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ABSTRACT
NOVEL CELLULAR TARGETS OF ASPIRIN IN CHEMOPREVENTION:
STUDIES ON P53, G6PD AND C-MYC
GUOQIANG AI
2016
Background
Aspirin has generated a significant interest in recent years as a potential
chemopreventive agent supported by strong evidence from epidemiological data; however,
the mechanisms are not well understood. The objective of this dissertation is to identify
novel cyclooxygenase (COX)-independent pathways by which aspirin exerts its anticancer effects in epithelial cancer cell lines. We investigated the effect of aspirin on p53,
glucose 6-phosphate dehydrogenase (G6PD), and c-Myc, all of which are known to play a
major role in cancer development. p53 is a tumor suppressor protein, often mutated in
cancers causing its inactivation. Expression of G6PD is elevated in many cancers, and this
significantly contributes to increased synthesis of DNA and RNA through the production
of pentose sugars. c-Myc is a transcription factor (TF), which is mutated and constitutively
activated in 20% of all cancers. The studies on p53 and G6PD are an extension of the
previous work carried out in our laboratory, in which we demonstrated the ability of aspirin
to acetylate these proteins in MDA-MB-231 human breast and HCT 116 human colon
cancer cells, leading to modulation of their functions. It was therefore important to extend
these studies to other cancer cell lines to gain an insight into the mechanisms of
chemoprevention by aspirin, and to more clearly establish the generality of the
observations. The studies on c-Myc are novel, and few reports exist on aspirin’s ability to
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modulate c-Myc functions in the literature.
Understanding these aspirin-mediated chemopreventive mechanisms is very
important because they have translatable implications for chemoprevention and
chemotherapy. This is because: 1) nearly 50% of all tumors contain mutated p53 with
varying degree of inactivation, and therefore, it is desirable to identify molecules that
reactivate mutant p53 to curtail the cancer cell growth; 2) G6PD catalyzes the first reaction
in the pentose phosphate pathway (PPP), and involved in the synthesis of ribose sugars
required for nucleic acid synthesis, important for tumor growth. The expression levels of
G6PD are elevated in many cancers, and therefore, it is a potential target in cancer
treatment. 3) Because of the established role of c-Myc in cancer, it has been considered as
an important target in cancer therapy. Our central hypothesis was that a significant portion
of aspirin’s anti-cancer effects occur through modulation of the functional activity of p53,
G6PD and c-Myc, collectively contributing to suppression of cancer cell growth.
Results
Our studies demonstrate that aspirin exposure causes acetylation of wild-type p53
in HCT 116 cells and mutant p53 in HT-29 human colon cancer cells. Acetylated p53 was
localized to the nucleus, and this was associated with an increased expression of p21CIP1, a
protein involved in cell cycle arrest. Mass spectrometry (MS) analysis of aspirin acetylated
recombinant wild-type p53 identified 10 lysines as targets of aspirin-mediated acetylation.
This included 5 lysines in the DNA binding domain, 4 in the nuclear localization signal
domain and 1 in the C-terminal regulatory domain. Five of these lysines acetylated by
aspirin were common to the sites that are naturally acetylated by acetyltransferases. This
included lysine 120 and 320, which were previously demonstrated to be important for the

xviii

expression of p21CIP1 and Bax. This suggests that chemical acetylation of p53 by aspirin
may lead to expression of p53-target genes in cancer cells harboring wild-type or mutant
p53.
Aspirin acetylated G6PD in both HCT 116 and HT-29 cells; however, the extent of
acetylation was greater in HCT 116 cells than HT-29 cells. Increased acetylation of G6PD
was associated with an increased inhibition of the enzyme activity. Mass spectrometry
analysis revealed that aspirin targeted 14 lysines in G6PD; 4 in the NADP binding domain,
and 1 in the active site of the enzyme. It is likely that the observed inhibition of G6PD
enzyme activity by aspirin is due to acetylation of the essential lysine in the active site, or
the NADP substrate binding sites, or both. These results suggest that aspirin may contribute
to anti-cancer effect through inhibition of G6PD and reduced synthesis of pentose sugars.
We demonstrate that aspirin and its primary metabolite salicylic acid caused the
down-regulation of c-Myc protein and mRNAs in several human cancer cell lines. This
suggests that c-Myc regulation by aspirin and salicylic acid is likely to occur at both
transcriptional and post-translational levels. Down-regulation of the c-Myc protein was
partially sensitive to treatment with lactacystin, an inhibitor of 26S proteasomal pathway,
which suggests the involvement of cysteine proteases. This is the first detailed investigation
demonstrating the down-regulation of c-Myc by aspirin and salicylic acid in cancer cells.
Conclusion
Our findings suggest that, aspirin or its metabolite salicylic acid can target p53,
G6PD and c-Myc, leading to modulation of their functions within cells; collectively these
contribute to their anti-cancer effects in epithelial tissues.
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Chapter 1. Introduction
1.1

Aspirin as a drug
The century-old drug aspirin has sustained its reputation as a wonder drug since it

was first introduced in 1897 by Bayer, Germany. For more than a century, this simple
miraculous drug was used to treat a number of conditions, including fever, pain, rheumatic
fever, and inflammatory diseases, such as rheumatoid arthritis, pericarditis, and Kawasaki
disease. Aspirin is also used long-term, at low doses, to help prevent heart attacks, strokes,
and blood clot formation in people at high risk of developing blood clots1. It is one of the
most commonly used drug and its estimated consumption amount around the world is about
40,000 tons per year2. The history of aspirin goes back to almost 2400 years. The historical
records written by the famous Greek physician Hippocrates (circa 460-377 BC), show the
common uses of willow bark extract for alleviating the symptoms of inflammation, fever
and pain. The willow bark extract was used for centuries in different cultures around the
world as a remedy against a broad range of painful maladies3.
The history of aspirin is tied to the discovery of salicylic acid as the active
ingredient in the willow bark extract. In 1829, Henri Lerouxhad, a French chemist,
successfully extracted salicin (Salicyl alcohol glucoside) from the plant, and in 1838,
Raffaele Piria, an Italian chemist then split salicin into a sugar and salicylaldehyde and
converted the latter, by hydrolysis and oxidation, to salicylic acid. While the salicylic acid
was somewhat effective, it also caused digestive problems such as gastric irritation,
bleeding, and diarrhea. This led to a desire to chemically modify the structure of salicylic
acid to a better tolerable compound. Felix Hoffmann, a young chemist at Bayer, Germany,
synthesized acetyl salicylic acid by acetylating the hydroxyl group of salicylic acid with

2

acetyl chloride in 1897. This compound was named as aspirin, with “A” denoting acetyl
chloride, the “spir” from Spiraea ulmaria (the plant they derived the salicylic acid from)
and the 'in' was a then familiar name ending for medicines3. Aspirin has two functional
moieties; the acetyl and salicylic acid groups (see Figure 1.1). When aspirin was tested in
animal models at Bayer, it was found to have anti-pyretic, analgesic and anti-inflammatory
properties, therefore, Bayer made this drug available to the public as a powder in 1899 and
as tablets soon after. Aspirin was patented in February 19003.

Figure 1.1 Structure of salicylic acid and aspirin
1.2

Recommended dose, metabolism and side effects of aspirin
Depending on the conditions being treated, aspirin is used at a range of doses from

75 mg (antiplatelet, 81mg in the USA) to 325-600 mg /4-6h (analgesic) to 1.2 g /4-6h (antiinflammatory)4. Aspirin is mainly absorbed intact in the gastrointestinal (GI) tract5,6 and
later hydrolysed to the acetate and salicylate ions by esterases as it circulates in the plasma4.
Hydrolysis can also occur during passage through the liver and other organs. Following
low-dose aspirin, it is estimated that the peak plasma concentration of aspirin reaches
~7µM; however, analgesic and anti-inflammatory doses can yield plasma concentrations
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ranging from 30 to 150 µM4. The plasma salicylic acid concentrations obtained from the
hydrolysis of low-dose aspirin is estimated to be 15 µM, whereas the analgesic and antiinflammatory doses can yield concentrations ranging from 500 to 2500 µM4. Aspirin
metabolites are excreted mainly by the kidneys as salicyluric acid (75%), free salicylic acid
(10%), salicylic phenol (10%), and acyl glucuronides (5%), gentisic acid (< 1%), and 2,3dihydroxybenzoic acid7. When small doses (less than 250 mg in an adult) are ingested, all
aspirin’s metabolites proceed by first-order kinetics, with an elimination half-life of about
2.0 to 4.5 hours (h)8,9. When higher doses of aspirin are ingested (more than 4 g), the halflife of salicylic acid becomes much longer (15-30 h)10, because the biotransformation
pathways that form salicyluric acid and salicyl phenolic glucuronide become saturated11.
Although aspirin is widely used, it is known to cause adverse effects and toxicities.
This includes GI bleeding, hemorrhagic strokes, nephrotoxicity, and tinnitus. The plasma
of aspirin-treated patients has been shown to contain antibodies against acetylated albumin.
This is sometimes associated with a number of untoward immunological reactions such as
skin rashes and angioedema. Moreover, aspirin-intolerant patients are characterized by
asthma, rhinitis, and nasal polyps12, suggesting that the adverse effects of aspirin include
imbalance in immunological reactions. Another side effect of aspirin in children is Reye’s
syndrome which occurs due to fatty deterioration of liver cells13.
1.3

Mechanism of action of aspirin
The mechanism of action of aspirin was unknown for several decades; however, it

was used extensively as an effective therapeutic drug. In 1971, Sir John Vane, a British
pharmacologist, discovered that it irreversibly inactivates the cyclooxygenase (COX)
enzyme (prostaglandin H-synthase)14. A report published in 1975 by Roth et al for the first
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time discovered the acetylation mediated inhibition of COX leading to the decreased
synthesis of prostaglandins in human platelets15. The COX enzymes are involved in the
synthesis of cyclic endoperoxides from arachidonic acid (AA) forming prostaglandins,
prostacyclins, and thromboxane, which have a wide array of effects. Aspirin is unique
because it is the only non-steroidal anti-inflammatory drug (NSAID) that irreversibly
inactivates both isoforms of the COX enzymes (COX-1 and COX-2), which bring about
its anti-inflammatory, antipyretic and analgesic effects. Aspirin acetylates serine 529
(Ser529) of COX-1 and Ser516 of COX-216-18. Cyclooxygenase-1 is constitutively
expressed in platelets and in the gastric epithelial cells. In platelets, through the production
of thromboxane A2 (TXA2), it is responsible for platelet activation, whereas in gastric
epithelial cells, it causes gastric cytoprotection, through the generation of prostaglandin E2
(PGE2). Cyclooxygenase-2 is constitutively expressed in certain types of cells, such as
endothelial cells; however, its level is elevated during inflammation, and in cancer cells.
Although aspirin is able to inactivate both COXs, it is more selective to COX-1 than COX2 because the active site of the later is slightly larger, and therefore, the substrate AA
molecule is still able to squeeze past and get converted to 15-hydroxyeicosatetraenoic acid
(15-HETE)19,20. Aspirin is 166-fold more potent in inhibiting COX-1 than COX-221. Once
COX-1 is acetylated by aspirin, AA cannot gain access to its catalytic site for the life time
of the platelet. The restoration of the TXA2 biosynthesis in such individuals can occur only
with fresh platelet production22.
1.4

Acetylation of cellular proteins besides COX by aspirin and its significance
The ability of aspirin to acetylate COX was discovered in 197114; however, in the

following decades, attempts to identify newer targets were not seriously pursued.
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Experiments with radio-labeled 3H or

14

C aspirin demonstrated that aspirin acetylates

several proteins in vitro and in vivo through a trans-acetylation reactions12,23,24. Aspirin
acetylates human serum albumin and fibrinogen in vitro and in vivo18,25. It can also
acetylate several other proteins and biomolecules such as hemoglobin, DNA, RNA,
histones, transglutaminase, as well as other plasma constituents including hormones and
enzymes26,27. Aspirin also has been shown to acetylate γ-crystallins at lysine and cysteine
residues, this was implicated in its anti-cataract effects28,29. In a remarkable study, it was
found that in vivo administration of radio-labeled 3H or 14C aspirin to rats, led to the binding
of the acetyl group of aspirin to several proteins, glycoproteins and lipids of the stomach,
kidney, liver and bone marrow23, demonstrating that the acetyl group is able to reach distant
organs.
Aspirin is a systemic agent that has both beneficial and adverse effects throughout
the body. Its beneficial effects include its analgesic, anti-inflammatory, anti-thrombotic,
and cardioprotective properties30. Interestingly, several epidemiological studies carried out
in the past two decades showed that aspirin can decrease the incidence of cancers of various
epithelial tissues4,30. This is discussed in the later section (see section 1.5, page 7). While
the acetylation-mediated COX inhibition could explain many of these therapeutic effects,
it is believed that COX-independent pathways may also contribute to its yet-to-be
explained beneficial actions. In this context, it is important to note that aspirin has been
demonstrated to cause acetylation of multiple cellular proteins24, providing it the potential
to affect simultaneously multiple cellular pathways. Using antibodies specific for the
recognition of acetylated lysine residues, our group demonstrated that aspirin acetylates
multiple proteins in a dose-dependent manner in rat liver epithelial cells, and HCT 116

6

human colon cancer cells31,32. In HCT 116 cells32, aspirin acetylated at least 33 different
proteins which included histones, cytoskeletal and heat shock proteins, glycolytic and
pentose phosphate pathway (PPP) enzymes and ribosomal and mitochondrial proteins. It
is to be noted that in these studies only lysine acetylation sites were identified with the use
of anti-acetyl lysine antibody and Mass spectrometry (MS). In a recent study Bateman et
al reported the ability of aspirin to acetylate 120 different proteins in HCT-15 human
adenocarcinoma cells using an alkyne-aspirin (AspAlk) chemical reporter33, which was
also confirmed by another group34. The latter group showed that 523 proteins were
acetylated by aspirin within cells. It appears that in addition to lysine residues, aspirin can
also target serine and cysteine residues33. The identified enzymes in that report included
several metabolic pathway enzymes, structural proteins, proteins involved in translation,
proteasomal subunits, mitochondrial proteins, and histones. Among these, histones appear
to be most intriguing due to their prominent role in transcriptional regulation. Histone
acetylation can cause charge neutralization of basic lysine residues leading to changes in
the chromatin structure and transcription of genes. It is possible that chemical acetylation
by aspirin may play a role in shifting the equilibrium of the enzymatic acetylation
/deacetylation process that occurs naturally in cells bringing about major changes in gene
expression30.
Studies carried out in our laboratory also demonstrated that aspirin acetylates the
tumor suppressor protein, p53 at lysine 382 in WB rat liver cells carrying wild-type p53
and MDA-MB-231 breast cancer cells harboring a mutant form of p53 (codon 280, Arg to
Lys)31,35. This effect correlated with increased p53 DNA binding activity and expression
of two of its target genes, p21CIP1 and Bax. p21CIP1 binds to cyclin-dependent kinases
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(CDKs), and can arrest the cell cycle in DNA-damaged cells, allowing time for cells to
repair the DNA. Bax is a proapoptotic protein that regulates mitochondria-mediated
apoptosis. Aspirin also acetylated p53 in other cell lines carrying different p53 mutations31.
In another study, our group also showed that aspirin acetylated glucose-6-phosphate
dehydrogenase (G6PD) causing a decrease in its enzyme activity32.
Acetylation is a critical endogenous posttranslational modification that affects the
function of a wide array of proteins in the body36. The ubiquitous nature of acetylation was
demonstrated by Zhao et al who showed that more than 1000 proteins are naturally
acetylated in human liver cells37,38. These included 44 metabolic pathway enzymes
involved in glycolysis, fatty acid and glycogen metabolism, tricarboxylic acid and urea
cycles. Acetylation has been associated with the control of enzyme activity by activating,
inactivating or destabilizing metabolic enzymes38 and may allow cells to respond to
changes in metabolic demands39. Deregulated acetylation has been implicated in diseased
states such as cancer38. Aspirin’s ability to chemically acetylate endogenous proteins has
immense therapeutic significance and represents an emerging area of study.
1.5

Aspirin’s emerging anti-cancer properties
The epidemiological studies carried out in the last two decades showed a significant

correlation between regular aspirin use and reduced cancer incidence and mortality. This
is particularly evident for the cancers of the epithelial tissues. This inverse correlation is
now established for the cancers of the colon40-42, breast, prostate, lung and the skin43-46.
Animal and human studies also support a role for aspirin in chemo-prevention. Controlled
clinical trials showed the ability of aspirin to lower the occurrence of polyps and reduction
of recurrent adenomas in human patients47-49. Its use after the colorectal and breast cancer
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diagnosis was associated with a decreased risk and increased patients’ survival50,51. The
most significant cancer risk reduction was observed in the colon tissue; however, the
protective effect of aspirin differed slightly among other distal tissues52 (see Table 1.1).
Table 1.1 Incidence of cancer reduction by aspirin
Cancer type

Cancer reduction

Note

Colon

51 %

All dose

63 %

> 325 mg/day

90 %

Occasional aspirin use

73 %

Daily NSAID use

Stomach cancer

40-70 %

Regular aspirin take

Breast

25-30 %

325 mg/ day, > 5 years

Lung carcinoma

49 %

325 mg/ day, > 5 years

Prostate cancer

49 %

325 mg/ day, > 5 years

Esophageal cancer

The evidence that aspirin prevents cancer is compelling; therefore, understanding
the mechanism of its chemo-preventive properties has been the focus of research in many
laboratories. In the last 5 years, aspirin research has gained momentum because of the
interest took also by National Cancer Institute (NCI). In 2012, NCI listed in its website the
importance of understanding the mechanisms of chemo-preventive actions of aspirin under
“Provocative Questions”. To quote directly from the NCI: “What is the molecular
mechanism by which a drug (such as aspirin) that is chronically used for other indications
protects against cancer incidence and mortality?”53 The evidence in favor of aspirin to
prevent cancer accumulated significantly over the past 5 years. In view of this, in
September 2015, United State Preventive Services Task Force (USPSTF) has made a draft
recommendation statement on the use of low-dose aspirin for the primary prevention of
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cardiovascular disease (CVD) and colorectal cancer in adults who do not experience the
side effects of bleeding, within the age group 50 to 5954. Aspirin has gained the attention
of scientists, physicians and the public for its protective effect against cancer.
1.6

Aspirin and colorectal cancer
Colorectal cancer (CRC) is an important public health problem in the United States

as well as the whole world. It is the third most commonly diagnosed cancer in both men
and women with an estimated 132,000 new cases expected to occur every year in the USA.
It is also the third leading cause of cancer death55. According to the most recent
Surveillance, Epidemiology, and End Results Program (SEER) data (2004-2010), 5-year
survival for CRC is 64.7%, ranging from 89.8% for local stage disease to 12.9% for distant
metastatic disease56. Globally, colorectal cancer is the third most commonly diagnosed
cancer in males and the second in females, with an estimated 1.4 million new cases and
693,900 deaths occurring in 201257. Colorectal cancer incidence and mortality have
declined over the past 20 years, attributable to increased screening and introduction of new
drugs58,59.
Colorectal cancer can arise due to inherited mutated genes, or mutations acquired
in somatic cells during one’s life time. Hereditary colorectal cancer (hereditary nonpolyposis colon cancer, HNPCC) accounts for 20% of all colorectal cancers60. The DNA
mismatch-repair genes such as MLH1 (MutL Homolog 1) and MSH2 (MutS protein
homolog 2), are among the most frequent mutated genes in HNPCC. Genomic instability
arising from mismatch-repair deficiency significantly increases the development of
HNPCC. Other genes that are also mutated in HNPCC include MSH6, a member in the
DNA mismatch-repair protein family, and MUTYH (MutY homologue) involved in base
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excision repair61.
In non-hereditary cases, the CRC originates from the intestinal crypt stem cells that
line the colon or rectum of the GI, due to mutations in proteins that regulate Wnt signaling
pathway, leading to increased signaling activity in the cells. This is regarded as an initiating
event in CRC61. The frequently mutated gene in CRC is the adenomatous polyposis coli
(APC) gene; this is clearly singled out as a key factor in the development of CRC. The
APC protein is involved in the destruction of β-catenin, a transcription factor (TF) that
regulate many oncogenes including c-Myc, cyclin D, vascular endothelial growth factor
(VEGF), c-jun, COX-2, and EGFR62-66. In the absence of APC, β-catenin accumulates to
high levels, and translocate to the nucleus where it activates the transcription of the protooncogenes, leading to uncontrolled cell proliferation. In some colorectal cancers, in
addition to APC mutation, β-catenin itself is mutated, which blocks its own degradation
leading to increased accumulation and activity. The inactivation of p53 through mutations
is the second key genetic alteration in CRC, and in most cases, both alleles of p53 are
inactivated. The mutational inactivation of transforming growth factor β receptor II
(TGFBR2) leading to inactivation of TGF-β signaling, is the third step in CRC. Other gene
mutations observed in CRC include SMAD family member 4 (SMAD 4), RAS, and BRAF,
which activate mitogen-activated protein kinase (MAPK) pathway, promoting cell
proliferation. In addition, colorectal cancers also have activating somatic mutations in
phosphatidylinositol 3-kinase (PI3KCA), which encodes the catalytic subunit of
phosphoinositide 3-kinase (PI3K). Additionally, the DCC (deleted in colorectal cancer)
gene appears to have a segment of a DNA deleted in CRC. c-Myc is a proto-oncogene,
often aberrantly expressed in CRC. It is reported that 67% of the colon cancers have c-Myc
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over-expression and 17% have c-Myc amplification which also contribute to CRC
development67. Regulated expression of all these genes are required to oppose the
malignant phenotype to prevent the normal cell becoming a cancer cell, and therefore, their
abnormal expression causes cancer phenotype68.
In addition to the mutations in tumor suppressor and proto-oncogenes, epigenetic
silencing of genes also contributes to CRC, this is often mediated by aberrant DNA
methylation. In the genome, under normal conditions, cytosine in the dinucleotide CpG
present in the area of repetitive DNA sequences, may be modified as 5-methyl cytosine in
regions excluding the “CpG islands”, located near the promotor of genes. In contrast, in
the colorectal cancer genome, some reduction in the methylated cytosine were observed in
CpG dinucleotides located in the repetitive DNA sequences; however, there was a
considerable increase in the acquisition of aberrant methylation within certain promotorassociated CpG islands. One of the genes that is silenced in this way is the DNA repair
gene MLH161.
Colorectal cancer is a prevalent malignancy associated with significant morbidity
and mortality. However, since the transition from precursor to the malignant state in CRC
takes around 15-20 years on average, a considerable window of opportunity exists for
effective intervention and prevention69. Compelling evidence from epidemiological studies
showed that NSAIDs particularly aspirin can suppress the colon carcinogenesis. In most
case-control and cohort studies, it was observed that regular aspirin use was associated with
reduced risk of CRC. A systematic review of case-control studies published in 2012
revealed a statistically significant decrease in the risk of developing CRC (OR = 0.62, 95%
CI: 0.58-0.67), when aspirin was used regularly as compared with non-users. Aspirin use
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also decreased significantly the proportion of cancers with distant metastasis (OR = 0.69,
95% CI: 0.57-0.83). In a second study involving a total of 662,424 men and women in the
Cancer Prevention Study II cohort showed that daily use of aspirin for at least 5 years was
associated with a 32% reduction in risk of CRC. Two cohort studies of United States health
professionals (47,363 men and 82,911 women) showed that regular aspirin users (≥ 2 times
/week) had 21% and 23% lower risk of developing CRC, during follow-up periods of 18
and 20 years respectively. Moreover, in a separate analysis of a Nurses Health Study
cohort, regular aspirin use also reduced the risk of death from CRC by 28% and risk of
death from any type of cancer by 12%70.
Aspirin’s ability to prevent CRC also came from clinical studies that were
originally designed to evaluate the prevention of CVD70. In four randomized studies,
dosage ranged from 75-1200 mg/ day, median treatment duration was 6 years and median
follow-up was 18.3 years. Treatment with aspirin (75-500 mg/ day) reduced the 20-year
risk of CRC by 24% and CRC-associated mortality by 35%. The benefit increased with
longer duration of aspirin use and seemed to be higher for proximal CRC compared to
distal CRC. In another study, the effect of daily use of aspirin was examined on long-term
risk of death due to all cancers. They included data from eight randomized trials (25,570
patients, 674 cancer deaths) and concluded that aspirin use reduced the risk of death due to
cancer (pooled OR = 0.79, p = 0.003), but the benefit was only apparent after 5 years of
treatment71.
1.7

Proposed mechanism of chemoprevention
The underlying mechanism leading to aspirin’s anti-cancer effect is enigmatic as

numerous protein targets and pathways have been proposed. Which of these primarily
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contributes to its anti-cancer effects is not clear. Aspirin consists of acetyl and salicylic
acid functional groups. One widely accepted mechanism is the acetylation-mediated
inhibition of COX-1 and COX-2, leading to decreased prostaglandin synthesis41. In
addition, aspirin and sodium salicylates also have been shown to suppress the expression
of COX-2 at the transcriptional level72. It is also important to note that COX-2 expression
is often elevated in many types of cancers73. The argument in favor of a COX-dependent
hypothesis is that decreased prostaglandin synthesis leads to decreased inflammation, and
hence decreased incidences in cancer. It is reported in the literature that, chronic
inflammation is often associated with the development of cancers165,166. Based on the
reported studies, it is clear that other pathways, beside COX, also play a role in aspirin’s
chemopreventive properties4,30,41. In this connection, multiple COX-independent
mechanisms affecting enzyme activity, TFs, cellular signaling and mitochondrial functions
have been proposed4,30,74.
Aspirin and salicylates have been found to inhibit IκB kinase (IKK) β and prevent
NF-κB activation both in vivo and in vitro75-77. Transcription of several proteins involved
in inflammatory responses and angiogenesis is promoted by NF-κB77; therefore, inhibition
of this pathway may also contribute to aspirin’s observed anticancer effects. Aspirin has
been shown to prevent the binding of c-Raf with Ras in vitro, leading to an interference
with extracellular-signal-regulated kinase (ERK) signaling78. This observation is important
because the ERK pathway is involved in cellular processes like proliferation,
differentiation and survival. In view of the high levels of Ras mutations observed in many
cancers leading to the activation of the ERK pathway79, the finding that aspirin interferes
with ERK signaling is very significant. Aspirin can also affect mitochondrial functions. It
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increases the mitochondrial membrane permeability, causing the release of cytochrome C,
resulting in the activation of caspases (executioner proteases) followed by cell apoptosis in
several cell lines80-82. A study by Pathi et al in colon cancer cells demonstrated that, aspirin
caused caspase-dependent proteolysis of Sp1, Sp3, and Sp4 (specificity protein) TFs,
which was associated with down-regulation of several Sp-regulated genes involved in cell
survival, proliferation and angiogenesis83. Another mechanism includes the inhibition of
mitochondrial calcium uptake by salicylic acid leading to anti-proliferative effects84. One
of the major oncogenic pathways in colon cancer is the Wnt /β-catenin pathway. Aspirin is
known to cause a concentration-dependent inhibition of this pathway in vitro85. Din et al
showed in colorectal cancer cells that aspirin inhibited mTOR signaling and this was
associated with the activation of AMP-activated protein kinase and induction of
autophagy86. Another report demonstrated that aspirin decreases the levels of epidermal
growth factor receptor (EGFR) during colorectal tumorigenesis and this was observed in
both cell culture models and colorectal patients87. In another study, it was demonstrated
that inhibition of 6-phosphofructo-1-kinase activity by aspirin and salicylic acid caused a
decrease in glucose consumption and inhibition of cell proliferation88. Law et al showed
that salicylates induced cell growth arrest is associated with inhibition of p70s6k and downregulation of c-Myc, cyclin D1, cyclin A and proliferating cell nuclear antigen. Thus,
numerous molecular targets have been discovered as aspirin’s targets; therefore, the anticancer effect observed cannot be attributed wholly to a single target or pathways74. It is
also not clear at this stage whether these identified proteins are the primary targets of
aspirin, or a secondary effect resulting from the direct action on primary targets.
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1.8

Significance of p53 in normal and cancer cells
p53 is a tumor suppressor protein; being a TF, it controls the cellular response to

stress signals through the induction of cell-cycle arrest, apoptosis, and senescence89,90. In
normal cells which are not exposed to stress, the level of p53 is very low, and has a very
short half-life (∼5-20 min91). However, exposure of cells to genotoxic agents, or UV, causes
stabilization and activation of p53 via post-translational modifications involving
phosphorylation and acetylation92,93. Acetylation stabilizes p53 by preventing its
degradation and helps in the recruitment of co-factors. The p53 binding sites have been
identified in several hundred genes, and depending upon the nature of stress, it can induce
or repress target genes transcription94. Activated p53 can induce p21CIP1, a protein involved
in cell cycle arrest, or Bax, a protein involved in apoptosis89,90. The array of genes regulated
by p53 include nearly 150 genes91, which affect various aspects of cellular functions
including cell cycle arrest, DNA repair, angiogenesis, inhibition of cell proliferation, and
apoptosis. Due to its important roles in maintaining the genetic stability, p53 is often
described as the “guardian of the genome”95 (see Figure 1.2).
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Figure 1.2 The role of p53 in DNA repair and apoptosis
In normal cells, p53 levels are low; however, in DNA-damaged cells (due to exposure from
UV or genotoxic agents), the levels of p53 rise due to post-translational modifications via
phosphorylation and acetylation. In DNA-damaged cells, it induces the expression of
p21CIP1, a protein involved in cell cycle arrest. This allows sufficient time to repair the
damaged DNA. p53 also induces DNA repair proteins, p48 and p53R2 to facilitate DNA
repair process. If the damaged DNA cannot be repaired, p53 can induce Bax protein. The
main role of Bax is to induce apoptosis through the release of cytochrome C form
mitochondria90,96.
p53 plays a significant role in monitoring various types of stress signals by inducing
the expression of several genes involved in cell cycle and apoptosis. Its turn-over and
functional activity are regulated by post-translational modifications. These modifications
occur through the covalent addition of functional groups such as phosphate, acetyl, methyl,
ubiquitin, to the p53 protein and cause conformational changes92. While lysines are the
targets for ubiquitination, acetylation, neddylation, methylation and sumoylation reactions
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(see Table 1.2); serine and threonine residues are the targets for phosphorylation
reactions92,97. The serine residues that are phosphorylated include S6, S9, S15, S20, S33,
S36, S37, S46, S149, S315, S376, S378, S392; and threonine residues that are
phosphorylated include T18, T55, T81, T150, T15594. Each of these post-translational
modifications plays a distinct role in the regulation of p53 turnover, localization, and
functional activity. The ubiquitination at lysines cause degradation through a proteasomal
pathway, acetylation at lysines and phosphorylation at serine/ threonine residues, lead to
its increased stability and activation as a TF92. The location of the various enzymes
(acetyltransferase) catalyzed lysine-specific modifications in p53 reported in the literature
are shown in Table 1.2. The p53 protein has 3 distinct domains: the N-terminal
transactivation domain (aa 1-42), the central DNA binding domain (aa 98-292), and the Cterminal domain containing tetramerization (aa 324-355) and regulatory domains (aa 363393)92.
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Table 1.2 Lysines are the targets for ubiquitination, acetylation, neddylation,
methylation and sumoylation reactions in p53
Protein
domain
Transactivation
domain

DNA binding
domain

Nuclear
localization
domain
Tetramerization
domain

Serial

Lysine
position

Acetyl
transferase
target

Methy

Sumoy

Neddy

Ubiquiti

lation

lation

lation

nation

1

K24

2

K101

3

K120

4

K132

5

K139

6

K164

7

K291

8

K292

9

K305

10

K319

11

K320

12

K321

13

K351

+

14

K357

+

15

K370

+

+

+

+

16

K372

+

+

+

+

17

K373

+

+

+

+

18

K381

+

19

K382

+

20

K386

+

+

+

+
+
+

+

+

+

+

NES, Near
C-terminal
domain

C-terminal
regulatory
domain

+
+

+
+

+

Studies show that acetylation has multiple effects on p53 activities: it can directly
bind to sequence specific promoters or interact with co-activators and co-repressors to
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regulate gene expression. Acetylation of p53 increases the stability, and thus, competes
with other lysine-dependent modifications that have inhibitory effects on p53 such as
methylation, ubiquitination, and neddylation98. Carboxy-terminal domain contains six
lysines (K370, K372, K373, K381, K382, and K386), all of which are targeted for
ubiquitination by MDM2, as well as acetylation by CBP/p300 acetyltransferases (see Table
1.2). In normal cells, (under no or low genotoxic conditions), ubiquitination of these six Cterminal lysines in p53 causes its degradation; however, exposure of cells to genotoxic
agents leads to acetylation and stabilization, and also an increase in DNA binding
activity99,100.
One of the most important observations made by researchers in the past two decades
is the role played by the p53 mutation in the development of cancer. It is reported that
nearly 58.6% of colorectal cancers contain a mutated p53 with varying levels of
inactivation101. Among these p53 mutations, some lead to partial inactivation; whereas in
others the mutation leads to full inactivation. Reports in the literature suggest that p53
mutations are distributed in all coding exons of the p53 gene, with a strong predominance
in exons 4-9 which encode the DNA-binding domain of the protein. Examination of 19,262
human cancer patients for the most common p53 mutations in the DNA binding domain
has identified 6 major “hotspots” in p53102,103. The percentage of distribution of mutations
among these patients examined are as follows: R248 (7%), R273 (6.7%), R175 (5.1%),
G245 (3.3%), R249 (2.9%) and R282 (2.9%). Due to the role of p53 in curtailing the cancer
growth, there have been attempts to identify drugs capable of reactivating mutant p53 as a
strategy to suppress tumor growth104-106. Small molecules such as CP-31398, PRIMA-1
(p53 reactivation and induction of massive apoptosis-1), Ellipticine, P53R3, and maleimide
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analogs, capable of reactivating mutant p53 forms have been identified and are being tested
in in vitro and in vivo models104-108. However, due to unfavorable pharmacokinetics or
toxicity, many of these compounds are not available for use in patients. Development of
novel mutant p53 targeting drugs, therefore, with different modes of action should increase
the likelihood of success in cancer treatment.
1.9

Significance of c-Myc in normal cell functions and in cancer
c-Myc is a TF that controls nearly 15% of the expression of all genes109. Its

functions involve both transcriptional activations as well as repression of many genes. It is
a nuclear DNA-binding protein that controls multiple cellular functions such as cell
proliferation, metabolism, apoptosis, growth, and differentiation67. The genes that
consistently emerge as activated by c-Myc include cyclin A2, B1, D1, D2, E1, and
CDK4110. c-Myc represses the CDK inhibitors p21, p51INK4A as well as genes involving
growth arrest such as Gadd45. This clearly suggests that, it can exert control over cell
cycle109. The involvement of c-Myc in the regulation of protein synthesis has been well
established. It was demonstrated that c-Myc induces the transcription of several ribosomal
proteins such as L3, L6, L23, and S15A109; thus, enhancing ribosomal biogenesis. It is
reported to also induce the transcription of eIF4E, an mRNA binding protein, important for
translation initiation; thus, c-Myc can regulate the translational processes within cells111.
c-Myc has been shown to have a repressive effect on collagen and β1-integrin gene
expressions, important for the anchorage-independent growth of cells and contributes to
the neoplastic transformation. Many pathways of cell metabolism are also regulated by cMyc, for example, several key enzymes of glucose metabolism including enolase A,
hexokinase II, lactate dehydrogenase A, phosphofructokinase and glucose transporters I,
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suggesting that it enhances glucose uptake and glycolysis in cancer cells. Other metabolic
enzymes targeted and regulated by c-Myc include carbamoyl phosphate synthase, aspartate
transcarbamylase, dihydroorotase (CAD) and ornithine decarboxylase (ODC), essential for
nucleotide synthesis109. It is also important to note that c-Myc activates the expression of a
cluster of 6 microRNAs termed the miR-17 cluster suggesting that it can regulate the
stability or translational efficiency of mRNAs109. These examples suggest that, c-Myc
behaves as a global regulator of a group of genes, involved in cell cycle regulation,
metabolism, ribosomal biogenesis, and protein synthesis.
In normal cells, c-Myc levels are tightly regulated through degradation via an
ubiquitin-proteasome pathway112. However, in many cancers including colon cancer, the
c-Myc is constitutively activated and over-expressed, which leads to uncontrolled cell
proliferation. It is one of the most frequently amplified oncogenes in human cancers, and
c-Myc alterations are observed in a variety of cancers including colon, breast lung and
prostate cancers113,114. In 20% of all human cancers, c-Myc over-expression is observed,
and is associated with poor clinical outcome, aggressive metastatic phenotype, and
increased the tendency for relapse67,113. Overexpressed c-Myc accumulates in the promoter
regions of actively transcribing genes and causes increased transcriptional amplification,
producing higher levels of mRNAs and protein for a diverse set of genes115. Thus,
deregulated expression of c-Myc is a hallmark of cancer. Because of its role in cancer, cMyc is an ideal target for cancer treatment116 and despite the best efforts, no drugs that
target c-Myc has been identified for the treatment of human cancer.
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Figure 1.3 Normal function of c-Myc and its deregulation causing tumorigenesis
Regulated expression of c-Myc is important for many biological activities including cell
growth and division, cell-cycle progression, cell differentiation, angiogenesis, cell
metabolism, cell adhesion and motility, and apoptosis. C-Myc is often mutated in many
cancers, and its deregulation causes increased gene expression, genomic instability,
uncontrolled cell proliferation, evasion from immune surveillance, growth factor
independence, and immortalization67,117.

1.10 Significance of G6PD in cancer
Glucose-6-phosphate dehydrogenase is an important regulatory enzyme in the PPP,
and produces ribose-5-phosphates essential for RNA and DNA synthesis in rapidly
dividing cells118,119. It also produces the reducing power, the nicotinamide adenine
dinucleotide phosphate (reduced form, NADPH), essential for the neutralization of
oxidative stress, e.g., NADPH is required to maintain the reduced form of glutathione,
which serves to detoxify free radicals and peroxides118,119. NADPH generated in the PPP
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is also important for the reductive biosynthesis of fatty acids. Therefore, G6PD plays an
important role under normal physiological state, and in rapidly dividing normal cells.
Within the human cells, two isoforms of the G6PD have been reported120. Glucose-6phosphate dehydrogenase isoform a has a total of 545 amino acids and the isoform b has a
total of 515 amino acids. Isoform b is identical to isoform a except that it lacks the first 30
amino acids in the -NH2 terminus. It is reported that isoform b represents the functionally
active G6PD enzyme120 and accordingly, most of the studies in literature has been reported
on this isoform121.
Within the cells, G6PD exists as a mixture of monomer, dimer, tetramer and hexamer;
but only the dimer and tetrameric forms of the enzyme are catalytically active122. The active
enzyme exists in a dimer ↔ tetramer equilibrium. In the human isoform b, lysine 205
(K205) located within the highly conserved peptide RIDHYLGK (residues 198-205, a
single letter amino acid code in isoform b) has been shown to be important for catalysis123.
It is reported that G6PD isoform b (short form) is naturally acetylated at 7 lysine residues,
and this included K89, K171, K386, K403, K432, K497, and K51436,122. These modified
lysines in the isoform b correspond to K119, K201, K416, K433, K462, K527 and K544
in G6PD isoform a (long form). The activity of G6PD appears to be negatively regulated
by acetylation mediated by cellular lysine acetyltransferases of a lysine at position 403
(K403)122. They demonstrated that K403 acetylated G6PD is incapable of forming active
dimers and displays a complete loss of activity.
Several studies demonstrated that G6PD is over-expressed in multiple cancers
including breast, colon, endometrial, cervical, prostatic and lung cancers118,119,124-127. The
NADPH and ribose-5-phosphates are essential products generated in the PPP, important
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for cancer cell growth, through their contribution to the nucleic acid biosynthesis as well
as protection against oxidative stress. In fact, it is reported that ectopic expression of G6PD
in NIH3T3 cells significantly increased intracellular levels of NADPH and promoted
anchorage-independent cell growth128,129. Due to its important role in cancer development,
and increased expression in cancers, it is argued that G6PD is a potential therapeutic target
for cancer treatment119. For example, several studies have demonstrated the potential of
inhibiting G6PD with the use of dehydroepiandrosterone to reduce cell proliferation in
vitro and in vivo130,131. In our previous study, we demonstrated that aspirin acetylated G6PD
in HCT 116 cells leading to a decrease in its enzyme activity, suggesting the possibility
that it may play a role in aspirin’s chemopreventive actions32.
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Figure 1.4 Aspirin’s effect on PPP (A) and the naturally acetylated sites on G6PD by
acetyltransferases (B)
A, Glucose is oxidized within cells through glycolysis and PPP. Among the different
enzymes of the glycolysis and PPP acetylated by aspirin, it was demonstrated that
acetylation of G6PD leads to inhibition of its enzyme activity; it is indicated in red text. B,
G6PD is naturally acetylated by cellular acetyltransferases at 7 lysine residues, located in
both NADP-binding domain and C-terminal domain (see text for details).

1.11 Regulation G6PD by p53
Although p53 is a TF and G6PD is a metabolic enzyme, both having distinct
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functions, a report published in 2011 by Jiang et al demonstrated that, in normal cells, wildtype p53 regulates G6PD activity132. This was the first demonstration of the regulation of
G6PD activity by the tumor suppressor protein, p53. Glucose-6-phosphate dehydrogenase
activity requires dimerization or tetramerization of the protein132. In that report Jiang et al
demonstrated that in normal cells, wild-type p53 binds to G6PD and prevents its
dimerization required for its activity; whereas, in tumor cells harboring mutant p53, it fails
to bind G6PD, and therefore is unable to inhibit its activity. This inability of mutant p53 to
inhibit G6PD has been linked to increased consumption of glucose and growth in tumor
cells132. Thus, in normal cells, the ability of wild-type p53 to interfere with dimerization of
G6PD represents a novel regulatory function recognized for p53, leading to the reduced
synthesis of ribose sugars through the PPP.
1.12 Rationale and hypothesis
As discussed earlier, aspirin (acetylsalicylic acid) consists of 2 functional moieties,
acetyl and salicylate groups, both of which have their own distinct targets. Aspirin is
rapidly metabolized in the body to produce salicylic acid by esterases. Unlike the short
half-life of aspirin (20 mins), salicylic acid has a much longer half-life (4-6 h)4,70. Cells
within the body are exposed both to the intact aspirin as well as the free salicylic acid; thus,
an opportunity exists for both functional groups to affect the protein functions in exposed
tissues. While the acetyl group causes inactivation of COX through acetylation of serine
residues, the salicylate group has been shown to bind to 5 distinct cellular proteins till date:
IκB kinase (IKK) β, AMP-activated protein kinase133, high mobility group box1
proteins134, CDK2135, and Glyceraldehyde 3-Phosphate Dehydrogenase (GAPDH)136. The
identification of aspirin acetylation targets and identification of salicylic acid binding
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targets have been an emerging area of aspirin research in the last 6 years. Studies carried
out from our laboratory demonstrated that aspirin acetylates multiple cellular proteins32.
Acetylation targets of aspirin identified by our group include the tumor suppressor protein
p53, enzymes of the glycolytic pathway, cytoskeletal proteins, histones, ribosomal and
mitochondrial proteins32,35. Our studies also showed that aspirin acetylated G6PD in the
PPP32. Assays carried out for many of the glycolytic enzymes suggested that acetylation,
in most cases, does not affect the enzyme activity, and thus, has neutral impact on bulk
protein functions30,32. Among the several proteins that were identified as targets of aspirin,
we believe that acetylation of p53 and G6PD are important targets contributing to its anticancer effects. This is because, our previous data suggests that acetylation of p53 and
G6PD had an effect on their functional activity.
Rationale for the studies on p53
It was previously reported that acetylation of wild-type p53 in WB rat liver cells
and MDA-MB-231 breast cancer cells, harboring mutant p53 (R280K), caused increased
DNA binding activity and induction of its target gene expression such as p21CIP1 and Bax35.
In a recent study, Huang et al showed that phospho-aspirin, a derivative of aspirin, also
caused acetylation of p53 and induction of p21CIP1 protein in breast cancer cells137,138,
further supporting our previously published results35. In the present study, to validate our
previous observations, we used HCT 116 and HT-29 colon cancer cells as a model to
determine whether aspirin would cause acetylation of p53 and induction of p21CIP1
expression. HCT 116 is a human colorectal adenocarcinama cell line with wild-type p53
and HT-29 is a colorectal carcinoma cell line with mutant p53 (R273H)139. p53 is mutated
and deactivated in 50% of all cancers, and its reactivation is highly desirable to curtail the
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cancer cell growth105-108. In normal cells, p53 is naturally activated through acetylation and
phosphorylation (see Figure 1.2, page 16). Interestingly, in vitro acetylation by
acetyltransferases reactivates mutant p53 and restores the DNA binding property140,
suggesting the concept that acetylation alone can activate mutant p53. We hypothesized
that aspirin’s anti-cancer effect in epithelial tissues may involve acetylation-mediated
reactivation of mutant p53, leading to suppression of cancer cell growth.
p53 in its 393 amino acid long sequence contains a total of 20 lysine residues; of
these, 10 lysines are naturally acetylated by cellular acetyltransferase (see Table 1.2, page
18). It has been shown that sequences specific acetylation of lysines affects the turnover of
the p53 protein as well as target gene expression92. One of our major goals in this study
was to identify the lysine sites that are targeted by aspirin and comparison of these to the
sites that are naturally acetylated by acetyltransferase. In this study, we attempted to
characterize p53 acetylation sites targeted by aspirin in recombinant wild-type p53 to gain
insight into how it may affect p53 functional activity and target gene expression.
Rationale for the studies on G6PD
As discussed above, G6PD is overexpressed in many cancers, including the
colorectal, prostate, lung and ovary. In a previous report, using the HCT 116 human colon
cancer cell line, we demonstrated that aspirin acetylated G6PD; this was associated with a
decrease in G6PD activity32. We hypothesized that aspirin’s ability to acetylate G6PD
and the associated inhibition of the enzyme activity is due to acetylation of lysines in
the NAPD binding domain and/or the essential lysine located in the active site of the
enzyme. Glucose-6-phosphate dehydrogenase isoform a, contains 29 lysines. In order to
gain insights into the mechanism of aspirin-mediated inhibition, MS studies were
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performed on recombinant G6PD acetylated by aspirin in vitro. In the present study, we
also studied the comparative effects of aspirin on G6PD enzyme activity in HCT 116 cells
and HT-29 human colon cancer cells.
Rationale for the studies on c-Myc
Over-expression of c-Myc arising from genetic alterations due to mutation or gene
amplification is observed in 20% of all cancers. c-Myc contributes to the transformation of
normal cells to cancer cells through uncontrolled cellular growth and proliferation. During
tumorigenesis, it influences cellular adhesion, metabolism, angiogenesis and causes
genomic instability, thus, it is a central driver in many cancers. We hypothesized that
aspirin or its primary metabolite, salicylic acid may down-regulate c-Myc protein and
mRNA levels, leading to an inhibition of cell proliferation; thus, contributes to its
anti-cancer effect. Therefore, experiments were performed in multiple colon cancer cells
to determine the effect of aspirin and salicylic acid on c-Myc expression.
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Chapter 2. Materials and Methods
2.1

Materials

Chemicals (All chemicals used were analytical or molecular biology grade)
30% Acrylamide/ Bis solution (Bio-Rad)
A/G agarose slurry (Santa Cruz)
Acetone (Sigma)
Agarose (Lonza)
Ammonium persulfate (Bio-Rad)
Ampicillin (Sigma)
Aspirin (Sigma)
Bovine serum albumin (Sigma)
Bromophenol blue (Sigma)
Calpeptin (EMD-Millipore)
Chloroform (Sigma)
DMSO, Dimethyl Sulfoxide (Sigma)
DTT, Dithiothreitol (Sigma)
EDTA, Ethylenediaminetetraacetic acid (Sigma)
Ethanol (Sigma)
Formaldehyde (Sigma)
Glycerol (Fisher)
Glycine (Fisher)
Isopropyl alcohol (Sigma)
Lactacystin (EMD-Millipore)
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LB Agar (Fisher)
LB Broth (Fisher)
Magnesium chloride (Fisher)
Methanol (Fisher)
MOPS, 3-(N-morpholino) propanesulfonic acid (Fisher)
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma)
Phosphate Buffered Saline pH 7.4 (Invitrogen)
PMSF, phenylmethylsulfonyl fluoride (Sigma)
Recombinant G6PD protein (isoform a) (Origene Inc)
Recombinant p53 (Active motif Inc)
Salicylic acid (Sigma)
Sodium chloride (Fisher)
Sodium citrate (Fisher)
Sodium dodecyl sulfate (Bio-Rad)
Sodium fluoride (Sigma)
Sodium orthovanadate (Sigma)
TEMED, N,N,N',N'-Tetramethylethylenediamine (Sigma)
Tris, (hydroxymethyl) aminomethane (Fisher)
Tween 20 (Sigma)
β-mercaptoethanol (Sigma)
[γ- 32P] ATP (MP Biochemical)
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Buffers and solutions
1× SSC buffer: 150 mM NaCl, 15 mM sodium citrate
10× MOPS buffer: 1L 0.2 M MOPS /NaOH, 20 mL 0.5 M EDTA
10× SDS electrophoresis buffer: 30 g Tris-base, 144 g glycine, 10 g SDS, dissolve
in distilled water, q.s. to 1L
4× Protein sample buffer: 50 mM Tris-Cl, 150 µL/mL β-mercaptoethanol, 2% SDS,
10% glycerol, 0.1% bromophenol blue
Extraction buffer: 10 mM Tris (pH 7.4), 15% glycerol, 0.4 M NaCl, 1mM EDTA,
0.5 mM PMSF, 0.5 mM DTT, 1 mM sodium orthovanadate
Hypotonic buffer: 10 mM HEPES, pH 7.9, 10 mM KCl, 3 mM MgCl2, 1 mM
dithiothreitol, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM sodium
orthovanadate and 1 mM NaF
Lysis buffer: 10mM Tris-Cl (pH 7.4), 150 mM NaCl, 15% glycerol, 1% Triton X100, 1mM PMSF, 1mM sodium orthovanadate, 1 mM sodium fluoride with
protease inhibitors
Protein transfer buffer: 11.6 g Tris base, 5.85 g glycine, 500 mL methanol, q.s. to
2L with distilled water
Washing buffer (TBS-T): 20 mM Tris-HC1 (pH 7.4), 11.5 g NaCl, 0.05% Tween
20, q.s. to 2L with distilled water
Cell culture media and other reagents
DNase/RNase-free distilled water (Invitrogen)
Eagle's Minimum Essential medium (ATCC)
Fetal bovine serum (Invitrogen)
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FuGENE transfection reagent (Promega)
Leibovitz's L-15 medium (Invitrogen)
McCoy 5A modified medium (Invitrogen)
Prestained SDS-PAGE standards broad range (Bio-Rad)
Prolong® Gold antifade reagent with DAPI (Life technologies)
Protease inhibitor cocktail (Roche)
Protein Assay Dye Reagent Concentrate (Bio-Rad)
Supersignal Wes Pico Chemiluminescent Substrate (Pierce)
TRIZOL reagent (Invitrogen)
Kits used
Full-length c-Myc plasmid DNA (human) (Origene)
Full-length p53 plasmid DNA (human) (Origene)
G6PD assay kit (Biovision Inc)
GeneJET Gel Extraction Kit (Thermo Scientific)
High efficiency GC5 competent cells (GENE CHoICE)
Immobilon-P transfer membrane (Millipore)
MiniElute gel extraction kit (Qiagen)
QIAPREP Spin Maxiprep Kit (Qiagen)
RadPrime DNA labeling system (Invitrogen)
Random primer DNA labeling kit (Takara Biotech)
Instruments and equipment
Balance (Mettler Toledo)
Biological safety cabinet (Labconco)
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Cellometer Auto T4 cell counter (Nexcelom)
Centrifuge (Hettich)
Electrophoresis apparatus (Life Technologies)
Epi Chemi II Darkroom (UVP)
Fluorescence microscope (Zeiss Axio)
Freezer (-80°C) (Fisher)
Gel dryer (Bio-Rad)
HPLC, High performance liquid chromatography (Beckman Coulter)
Incubator (Eppendorf)
Microplate reader (Molecular Devices)
Microscope (Nikon)
pH meter (Accumet)
Pipetter (Eppendorf)
Table-top centrifuge (Eppendorf)
Transfer apparatus (Bio-Rad)
UV stratelinker (Stratagene)
Water bath (Fisher)
Antibodies
Anti-Acetyl-p53 (lysine 382) antibody, anti-c-Myc antibody, anti-acetyl lysine
antibody, and anti-β-actin antibody were purchased from Cell Signaling Technology
(Danvers, MA), monoclonal anti-p53 antibody was purchased from Zymed Inc. (San
Francisco, CA), anti-acetyl lysine antibody was from ImmuneChem (Burnaby, Canada),
goat anti-rabbit IgG, anti-G6PD antibody, anti-PCNA antibody, and anti-p21 antibody
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were purchased from Santa Cruz Biotechnology (Dallas, TX). Goat-anti-rabbit IgG and
mouse goat anti-mouse IgG were from Bio-Rad. Alexa Fluor 488 secondary antibodies was
from Life Technologies (Carlsbad, CA).
2.2

Cell culture
HCT 116, HT-29, SW480, NCI-H226, cells were obtained from American Type

Culture Collection (ATCC). HCT 116 and HT-29 cells were grown in McCoy's 5A
Medium, SW480, and MDA-MB-231 in Leibovitz's L-15 Medium, NCI-H226 in RPMI1640 Medium, all containing 10% fetal bovine serum (FBS) for 12-24 h before the addition
of aspirin or salicylic acid for indicated concentrations and time.
2.3

Cell proliferation assay
Cells are seeded at 50% confluency overnight in recommended medium containing

10% FBS. Drugs were added at various concentrations and incubated for 48h. The floating
cells were collected from the conditioned media, and pooled with the trypsinized adhered
cells, and counted in the Nexcelom Cellometer Auto T4 cell counter. The viability of the
cells was determined by trypan blue staining using the same machine.
2.4

Preparation of cell lysate and Western blots
Cells were grown for 12-24 h at 50% confluency, treated with aspirin for indicated

times. Cells were washed with Phosphate Buffered Saline (PBS) and scraped in cell lysis
buffer. Protein estimation was done by Bradford Method. Fifty µg of proteins from each
sample was loaded onto a polyacrylamide gel (PAGE), immunoblotted with respective
primary

antibodies.

Immunoreactive

bands

were

visualized

using

enhanced

chemiluminescence (ECL) Western blotting system according to the manufacturer’s
instructions (Pierce) and the protein bands were detected in an Epi Chemi II Darkroom

36

(UVP) by ECL reagents. The intensities of each band were quantified using NIH ImageJ
software with wand tool plugin141.
2.5

Cell fractionation and isolation of nuclei
Cells were grown overnight, treated with drugs for indicated time, and scraped into

ice-cold PBS, washed twice with PBS. Cells were suspended in a hypotonic buffer, broken
using a Dounce homogenizer, cytoplasmic and nuclear extracts prepared as described
previously35.
All cell fractionation studies were carried out at 4°C as previously described142.
Cells were harvested by scraping into ice-cold PBS, washed once with ice-cold PBS,
resuspended in 0.8 mL of hypotonic buffer per cell pellet derived from two 100-mm petridish plates. Using a loose fitting Dounce homogenizer, cells were gently broken into
cytoplasmic and nuclear fractions as described earlier142. Nuclei were removed from cell
homogenate by low-speed centrifugation (1000 rpm for 4 min) in an Eppendorf centrifuge
and extracted with high salt buffer for 30 min at 4°C and then centrifuged at 15,000×g for
10 min. the supernatant represented nuclear extract, which was used for Western Blot
analysis. The crude post-nuclear cytoplasmic fraction was subjected to 15,000×g in an
Eppendosrf centrifuge for 10 min, the supernatant represents the cytoplasmic fraction.
2.6

Protein estimation by bradford method
A solution of 1 mg/mL bovine serum albumin (BSA) was prepared by dissolving

10 mg of BSA in 10 mL of autoclaved distilled water and this was used to prepare protein
standards for the calibration curve. The samples were then prepared for protein estimation
by taking 5 µl of each sample in 795 µl of autoclaved distilled water. To each of these
standards and samples, 200 µl of Protein Assay Dye Reagent Concentrate (Bio-Rad) was
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added and the resulting mixture vortexed. After 5 min, the absorbance of the standards and
samples was read at 595 nm. A graph of absorbance vs. concentration was plotted to
determine the concentration.
2.7

Immunoprecipitation
Cell lysates were prepared using cell lysis buffer. Two hundred µg of the total

protein was diluted to 1 mL with lysis buffer, imunoprecipitated with anti-acetyl lysine
antibody conjugated with agarose at 4°C overnight in a labquake. The samples were
centrifuged at 2500 rpm at 4°C and the supernatant was removed with a 1 mL insulin
syringe. The pellet was washed 3 times with lysis buffer. The proteins bound to agarose
were eluted using the trimethylamine buffer, and immunoblotted with the anti-G6PD
antibody.
2.8

Transforming E. coli cells with plasmid DNA carrying c-Myc
The full-length c-Myc plasmid DNA (human) cloned in the pCMV6-Entry vector

was obtained from Origene Corporation. The insert size of c-Myc in this plasmid was 1.4
kb. The competent E. coli (DH5-α) cells were thawed on ice and mixed by gently tapping
the tube. DNA (2ng) was added to 50 µl of competent cells and mixed; the samples were
then placed on ice for 30 mins. The cells were then heat shocked for 45 seconds in a 42°C
water bath and 450 µl of LB broth was added to each transformation reaction. These were
then incubated at 37°C for 1 h with shaking to recover the cells. The cells were then spread
on LB agar plates containing 200 µg/µl ampicillin and incubated overnight until the
colonies appeared.
2.9

Isolation of plasmid DNA and c-Myc DNA insert
A conical flask containing 200 mL of autoclaved LB broth containing 200 µg/µl
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ampicillin was inoculated with transformed cells (pCMV6-Entry vector carrying fulllength c-Myc) and placed on a shaker at 200 rpm (37°C) overnight. The next day, the cells
were centrifuged at 4000 rpm (4°C) and the supernatant discarded. The c-Myc plasmid
DNA was then isolated using the (QIAGEN) QIAPERP Spin Maxiprep Kit protocol and
the concentration of DNA was estimated at 260 nm in distilled water. The c-Myc plasmid
DNA was digested with MluI and EcoRI restriction enzyme to release the cDNA insert,
the digested DNA was run in an agarose gel, DNA purified using GeneJET Gel Extraction
Kit (Thermo Scientific).
2.10 RNA isolation and Northern blots
Total RNA was prepared from cells untreated or treated with drugs for the indicated
times using TRIzol reagent (Invitrogen). TRIzol (5 mL) reagent was added directly to the
cell culture plates, the cells were scraped, collected and incubated at 15-30°C for 5 mins.
Chloroform (0.2 mL per 1 mL of TRIzol reagent) was then added and the mixture was
shaken vigorously for 15 seconds. The samples were centrifuged at 12,000×g for 15 min
at 2-8°C. The aqueous phase was then transferred to a fresh tube and isopropyl alcohol (0.5
mL per 1 mL of TRIzol reagent) was added to precipitate the RNA. The sample was
incubated at 15-30°C for 10 min and centrifuged at 12,000 ×g for 10 min at 2-8°C. The
supernatant was discarded and the RNA pellet washed with 75% ethanol (1mL per 1 mL
of TRIzol reagent). The sample was mixed by vortexing and centrifuged at 7500 ×g for 5
min at 2-8°C. The supernatant was removed and the RNA pellet air dried and dissolved in
DNase/RNase-free water.
Twenty µg of the total RNA was analyzed on 1.2% agarose-formaldehyde gels,
transferred to nylon membranes and hybridized with
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P-labeled c-Myc cDNA in
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hybridization buffer. The blots were washed with 0.2×SSC containing 0.1% SDS for 1 h
at 65°C. The blots were dried and exposed to X-ray film.
2.11 Transfection studies
HCT 116 cells were grown in 100mm Petri dishes at 30-40% confluency for 16 h.
The cells were transfected with the expression vector carrying c-Myc cDNA using
FuGENE® 6 Transfection Reagent (Promega). Twenty-four hours after transfection, cells
left untreated with treated with aspirin or salicylic acid for another 30 h. Cell lysates were
prepared and immunoblotted with either anti-c-Myc antibody or anti-DDK antibody to
detect the endogenously or exogenously expressed c-Myc proteins.
2.12 Immunofluorescence
Cells were grown 12-16 h on a round microscope glass coverslip with 70%
confluency, and left untreated or treated with aspirin for 24 h. Cells were fixed in 4%
paraformaldehyde and incubated at room temperature (RT) with primary anti-acetyl p53
or anti-c-Myc antibody for 20 min, followed by 1 h incubation with Alexa Fluor 488
secondary antibodies. Images of cells were acquired using an AXIO Imager A1 microscope
(Carl Zeiss Microscopy GmbH) and a mounted Axio Cam MRc5 digital camera within 1
h of staining. For each picture, a color image was obtained as a TIFF file, using Windows
software. Adobe Photoshop CS 7.0 was used to merge the DAPI or Hoechst stained nuclei
and the Alexa Fluor 488 stained images.
2.13 G6PD activity assay
Sub-confluent cells were left untreated or treated with aspirin at the indicated
concentrations; cells lysed using the assay buffer according to the manufacturer’s
instructions (Biovision Inc.). One hundred µg of the sample was used from each treatment
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condition for the G6PD assays performed in a 96 well plate. After the reaction, the
absorbance was measured at 450 nm in a microplate reader (Molecular Devices).
2.14 High-performance liquid chromatography (HPLC)
The extraction of aspirin and salicylic acid following treatment to cells was
performed according to previously published method143 with slight modification. Cells
were treated with aspirin or salicylic acid for the indicated time. Cells were washed twice
with PBS, and lysed by sonication for 3 minutes using 1 mL of lysis buffer. The proteins
were precipitated out by mixing 100 µL of the sample with 200 µL of methanol, centrifuged
for 10 minutes at 14000 rpm. The amount of aspirin and its metabolite salicylic acid in the
aqueous solution was measured by HPLC. The amount of aspirin and its metabolite
salicylic acid in the aqueous solution was measured by HPLC by using ApolloTM C18 (4.6
× 250mm, 5µm) column maintained at 4°C. Methanol and 1% acetic acid at the ratio of 60:
40 (v/v) was used as a mobile phase at an isocratic flow rate of 0.8mL/min. Aspirin and
salicylic acid were detected by using UV detector at 275 nm and 295 nm wavelength
respectively. The retention times for aspirin and salicylic acid were 8.17 and 11.48 min
respectively. The concentrations inside the cell were calculated based on a standard curve
and the protein loaded.
2.15 Sample preparation for LC-MS/MS
Acetylation of the recombinant p53 (rp53, Active motif Inc.) was carried out in a
final volume of 33 µl, by incubating 5 µg of the protein with 100 µM aspirin for 12 h at
37°C in the presence of 50 mM MOPS (pH 7.4). For a negative control, an equal amount
of the protein was left untreated (no aspirin added), and incubated in the same buffer and
conditions. The reaction was stopped by adding ammonium acetate to a final concentration
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of 25 mM. To process these samples for MS analysis, 1 µg of the treated protein was
removed, lyophilized, and resuspended in 20 µl of 50 mM ammonium bicarbonate in
preparation for either a trypsin or a chymotrypsin digest. To initiate the digest, reduction,
alkylation procedure, 50 ng of the protease was added for an overnight digestion at 37°C.
The next day, the digested sample was reduced with 2 mM dithiothreitol (DTT) for 30 min,
with shaking at 60°C, and alkylated with 10 mM iodoacetamide (IAA) for 30 min in the
dark at RT. Finally, the alkylation reaction was quenched with 10 mM cysteine for 30 min
at RT in the dark. A second 50 ng of the aliquot of the protease was added for 3 h, to
completely digest the sample. After digestion was complete, samples were lyophilized in
a vacuum centrifuge and resuspended in 5 % acetonitrile, 0.05% formic acid and
immediately loaded on a reverse phase nano-spray tip for LC-MS/MS analysis. For routine
LC-MS/MS analysis, 2% of the peptide digest was loaded on a 70 µm x 5 cm packed
reverse phase magic C18 AQ (Michrom) nano-spray tip, using the autosampler function of
an Agilent 1200 HPLC. For higher coverage mapping, 15% of the peptide digest was
loaded on a single-sample dedicated nano-spray tip manually, using a pressure bomb, and
washed after installation on the HPLC of a Thermo LTQ mass spectrometer with 5%
methanol, 0.1% formic acid, for 10 min with a flow rate of 600 nl/min (about 10 column
volumes = 6.6 µl).
For LC-MS/MS runs, an LTQ ion trap mass spectrometer (Thermo) was equipped
with nano-electrospray ionization source. The peptides were eluted and analyzed in an LCMS/MS run, using a 5-15% methanol gradient over 2.5 minutes, followed by a 15-60%
methanol gradient for 67 minutes, a 60% methanol isocratic step of 4 min, ending with a 3
minute 95% methanol step, with all solvents containing 0.1% formic acid. A full MS survey
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scan is performed every 3 seconds and the top 7 peaks were selected to collect MS/MS
fragmentation spectrum, which were acquired in the data-dependent mode. The raw full
spectrum, and fragmentation spectrum data was converted to MGF format, using MM File
conversion (MassMatrix), which was analyzed in a Mascot v2.3 (Matrix Sciences) search
with the whole human proteome, to identify peptides harboring an acetyl modification.
Specifically, Mascot search parameters include: precursor and fragment ion mass tolerance
were set at 1.5 and 0.8 Da, respectively, and allowed for 1

13

C incorporation. Fixed

carbamidomethyl-cysteine modification, variable methionine-oxidation, and variable
lysine acetylation were allowed in the Mascot search against the complete human proteome
(NCBI 20110407). Because acetylation blocks trypsin cleavage, and because chymotrypsin
cleavage is often incomplete, three missed trypsin cleavage sites were allowed in the
Mascot search. The ion score/Expect cut off score was set for 0.1 and peptides. The Mascot
results file was further processed in both Scaffold (Proteome Software) and ProteoIQ
(NuSep), for additional data mining. In Scaffold, an X!Tandem (The global Proteome
Machine Organization) search was included in the data analysis and upload. When possible
ion extracted chromatograms for acetylated peptides were produced, using ProteoIQ, to
demonstrate peptide abundance after aspirin treatment, using MS1 ion signal intensity.
2.16 Protein modeling
The FASTA sequence of recombinant p53 protein (NP_000537.3), and G6PD
(NP_000393) were obtained from NCBI database. These sequences were submitted to the
SAM protein modeling server144. The coordinates of the atoms obtained via email from the
server were copied into a notepad and was saved as a text file. The text file was then opened
in the Rasmol protein modeling software (http://www.openrasmol.org/). The locations of
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lysine were mapped using the command line in the software.
2.17 Statistical analysis
All experiments were repeated 3-6 times independent of each other. One-way
ANOVA followed by Newman-Keuls multiple comparison tests were adopted to compare
group differences to control and significance was defined as P < 0.05.
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Chapter 3. Aspirin Acetylates Wild-type and Mutant p53 in Colon Cancer Cells:
Identification of Aspirin Acetylated Sites on Recombinant p53
This work has been published in Tumour Biol. (2015). DOI: 10.1007/s13277-015-4438-3
3.1

Abstract
Aspirin’s ability to inhibit cell proliferation and induce apoptosis in cancer cell lines

is considered to be an important mechanism for its anti-cancer effects. We previously
demonstrated that aspirin acetylated the tumor suppressor protein p53, at lysine 382 in
MDA-MB-231 human breast cancer cells. Here, we extended these observations to human
colon cancer cells, HCT 116 harboring wild-type p53, and HT-29 containing mutant p53.
We demonstrate that aspirin induced acetylation of p53 in both cell lines in a concentrationdependent manner. Aspirin acetylated p53 was localized to the nucleus. In both cell lines,
aspirin induced p21CIP1. Aspirin also acetylated recombinant p53 (rp53) in-vitro suggesting
that it occurs through a non-enzymatic chemical reaction. Mass spectrometry analysis and
immunoblotting identified 10 acetylated lysines on rp53, and molecular modeling showed
that all lysines targeted by aspirin are surface exposed. Five of these lysines are localized
to the DNA binding domain, 4 to the nuclear localization signal domain, and 1 to the Cterminal regulatory domain. Our results suggest that aspirin’s anti-cancer effect may
involve acetylation and activation of wild-type and mutant p53 and induction of target gene
expression. This is the first report attempting to characterize p53 acetylation sites targeted
by aspirin.
3.2

Results
In this chapter, we used HCT 116 and HT-29 colon cancer cells as a model to

determine whether aspirin would cause acetylation of p53 and induction of p21CIP1
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expression. HCT 116 is a human colorectal adenocarcinoma cell line with wild-type p53
and HT-29 is a colorectal carcinoma cell line with mutant p53 (R273H)139. We used MS
and immunoblotting to identify the acetylation sites by aspirin on recombinant p53 in vitro.
These data along with our previous report35, suggest that aspirin’s ability to acetylate p53
may represent an important mechanism for its anti-cancer actions.
3.2.1

Aspirin acetylated p53 at lysine 382 in a concentration-dependent manner in
HCT 116 and HT-29 cells
To determine the ability of aspirin to acetylate p53, cells were left untreated or

treated with aspirin at different concentration for 24 h, cell lysates were prepared and
immunoblotted with the anti-acetyl p53 (K382) antibody. Figure 3.1 A and B demonstrate
that in both cell types, aspirin acetylated p53 in a concentration dependent manner at lysine
382. Acetylation was observed beginning at 0.05 mM in HCT 116 cells, and 0.25 mM in
HT-29 cells. In both cell lines, acetylation of p53 was progressively increased at higher
concentrations of aspirin. When the samples representing the blots of A and B were
immunoblotted with anti-p53 antibody, we observed a slight increase in the levels of p53
following aspirin exposure in both HCT116 (Figure 3.1 C) and HT-29 cells (Figure 3.1 D).
For example, in HCT 116 cells, aspirin induced a 2-fold increase in acetylated p53 with
0.25 mM concentration compared to control lane (e.g., compare lanes 1 and 4 in Figure 3.1
C). This was also observed in HT-29 cells; the level of p53 was 1.8 fold higher at 0.5 mM
aspirin as compared to the levels in the untreated control (lanes 1 and 4 in Figure 3.1 D).
This slight increase in p53 levels possibly reflects the stabilization of p53 that has been
reported following acetylation92. Reprobing the blots of Figure 3.1 A and B showed that all
lanes contain similar amounts of β-actin (E and F).
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Figure 3.1 Aspirin acetylates p53 in HCT 116 (A) and HT-29 (B) cells
A and B, respectively represent anti-acetyl-p53 antibody immunoblots of HCT 116 and HT29 cells treated with aspirin at different concentrations for 24 h. For C and D, samples
representing A and B, were respectively immunoblotted with anti-p53 antibody. For E and
F, samples representing A and B were probed with anti-β-actin antibody. Quantification of
the intensity of bands in blots A and B are indicated under each band, the fold induction is
compared with the lowest aspirin concentration (lane 2).

We next examined the time course of p53 acetylation in HCT 116 cells. For this,
cells were treated with aspirin at 0.25 mM aspirin for different time points, lysates prepared
and immunoblotted with anti-acetyl p53 antibody (K382). Figure 3.2 A demonstrates that
aspirin-induced acetylation was detected in HCT 116 cells at 2 h and increased at later time
points. These samples contained similar amounts of p53 (Figure 3.2 B) and β-actin (Figure
3.2 C).
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Figure 3.2 Time course of acetylation of p53 by aspirin in HCT 116 cells
A, anti-acetyl-p53 antibody immunoblots of HCT 116 cells treated with aspirin 0.25 mM
for different time points. B, anti-p53 antibody immunoblots of samples representing A. C,
anti-β-actin antibody immunoblot of A. D represents the quantification of the bands of blot
A expressed as a percentage of the intensity compared to the time point at 2 h.

3.2.2

Acetylated p53 is localized to the nucleus
p53 is predominantly a nuclear protein90. To determine the intracellular localization

of p53 in aspirin-treated cells, we carried out immunofluorescence studies. Cells were
untreated or treated with 0.25 mM aspirin for 24 h, and then incubated with the anti-acetyl
p53 antibody, and the acetylated p53 was detected using Alexa Fluor 488-labeled
secondary antibody. We observed that exposure of cells to aspirin-induced increased levels
of p53 acetylation (see Figure 3.3 B) as compared to untreated control (see Figure 3.3 A).
Figure 3.3 C and D represent the Hoechst-stained nuclei of untreated and treated cells,
respectively. When images of above two figures (see Figure 3.3 A with C and Figure 3.3 B
with D) are overlapped, it is clear that most of the acetylated p53 was localized to the
nucleus (see Figure 3.3 E and F).
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Figure 3.3 Aspirin acetylated p53 is localized to the nucleus
The top panel (A and B) shows immunofluorescence of acetylated p53 detected using the
anti-acetyl p53 antibody (K382). The middle panel (C and D) shows nuclear staining with
Hoechst. The lower panel (E and F) shows overlapped images of the top and middle panels.
Images of cells were acquired using a Zeiss Axio Imager A1 microscope at a magnification
of ×40.
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3.2.3

Aspirin exposure to HCT 116 and HT-29 cells induces p21CIP1 expression
Since p53 is a known inducer of p21CIP1 expression, we investigated if aspirin

would induce the expression of p21CIP1, a protein involved in cell cycle arrest. We exposed
HCT 116 cells at 0.25 mM for different time points from 2-24 h. Cell lysates were prepared
and equal amount of proteins were analyzed by immunoblotting with anti- p21CIP1
antibody. Figure 3.4 A shows that aspirin induces p21CIP1 protein beginning at 2 h;
however, maximal levels were detected 4-6 h. Interestingly, the protein levels gradually
decreased with longer time of aspirin exposure, and at 24 h the levels were similar to the
untreated control. These samples contained similar amounts of β-actin (see Figure 3.4 B).
These results showed that aspirin exposure to HCT 116 cells induces p21CIP1 protein levels
in a transient fashion. We also carried out experiments to determine if aspirin induces
p21CIP1 in HT-29 cells. When aspirin was used at lower concentrations such as 0.25 mM,
the results were variable in HT-29 cells and often only marginal induction of p21CIP1 was
observed; however, at higher concentrations such as 1 mM and above, p21CIP1 induction
was consistently observed (see Figure 3.4 C and D).
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Figure 3.4 Aspirin induces p21 protein level in HCT 116 and HT-29 cells
A and C represent the anti-p21 immunoblots of HCT 116 and HT-29 cells treated
respectively with aspirin at 0.25 mM and 1 mM for different time points. B and D, anti-βactin antibody immunoblots.

3.2.4

Mass spectrometry analysis identified 9 lysine residues as targets of aspirin
It is reported that p53 undergoes acetylation mediated by acetyltransferases at 10

lysine residues which include K120, K164, K305, K320, K370, K372, K373, K381, K382,
and K38698. Using anti-acetyl 53 antibody, specific for lysine 382 (K382), we established
that aspirin acetylates lysine 382 on p53 (Figure 3.1). To determine which of the naturally
acetylatable lysine sites are targeted by aspirin, we carried out MS analysis of the in vitro
acetylated human recombinant wild-type p53 (rp53). Three µg of the rp53 was incubated
with 0.25 mM aspirin for 12 h and analyzed first for the acetylation of K382 using antiacetyl p53 antibody. Figure 3.5 A demonstrates that rp53 is acetylated at K382 by aspirin.
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Figure 3.5 Mass spectrometry analysis of rp53
A, In Vitro acetylation of rp53 by aspirin. For A, 5 ng of the in vitro acetylated rp53 was
immunoblotted with the anti-acetyl p53 antibody specific to K382. B and C, respectively
represent MS/MS fragmentation spectra showing an acetyl modification of K164 (B) and
K320 (C). B, The Mascot ion score = 89, Expect = 1.5×10-9, and MS parent ion error was
0.5 Da. The mapped acetylated lysine position (peptide position #6) is supported by b5, b6,
b10, y10,y11, and y12 ions that hit or flank the PTM position (circled in blue), which is
also a blocked trypsin cleavage site AMAIYK*QSQHMTEVVR. C, The Mascot ion score
= 25, Expect = 1.8×10-2, and MS parent ion error was 2.08 Da. The mapped acetylated
lysine position (peptide position #1) is supported by b1, b2, and y8 ions that hit or flank
the PTM position (circled in blue), which is also a blocked trypsin cleavage site:
K*KPLDGEYF; however, resistance to trypsin cleavage could also be influenced by the
proximal proline residue. Additional acetylated peptides in the trypsin digest agree with
PTM mapping to this position.
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An aliquot of the in vitro acetylated rp53 representing the blots in Figure 3.5 A was
subjected to MS analysis for the identification of acetylation sites. Based on the MS, we
identified a total of 9 lysine residues as the target of aspirin-mediated acetylation (see Table
3.1). Figure 3.5 B and C shows the spectra obtained from peptides spanning K164 and
K320 acetylated by aspirin. The spectra obtained for other sites (K120, K132, K139, K292,
K305, K319 and K3210 are shown in Figure 3.7 to Figure 3.13). The peptide digests
covered 82% of the total p53 sequence (see Figure 3.6). The identified aspirin acetylated
lysine residues include K120, K132, K139, K164, K292, K305, K319, K320, and K321.
These residues encompass the DNA binding and the NLS domains on p53 (see Table 3.1).
These results taken together with the results obtained from immunoblotting (Figure 3.1 A,
page 46 and Figure 3.5 A; K382) show that aspirin acetylates a total of 10 lysine residues
on wild-type p53.
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Table 3.1 The aspirin acetylated lysine residues identified in this study and the
naturally modified lysines on p53
Lysine

Aspirin

Acetyltransferase

position

target

target

K120

+

+

4

K132

+

5

K139

+

6

K164

+

7

K291

8

K292

+

9

K305

+

Nuclear localization

10

K319

+

domain

11

K320

+

12

K321

+

13

K351

14

K357

15

K370

+

16

K372

+

C-terminal regulatory

17

K373

+

domain

18

K381

+

19

K382

20

K386

Protein domain

Serial

Transactivation domain

1

K24

2

K101

3
DNA binding domain

Tetramerization domain
NES, Near C-terminal
domain

+*

+

+
+

+
+

*: K382 was identified as aspirin-mediated acetylation target by immunoblotting, the
others were identified through MS.
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Figure 3.6 p53 sequence coverage and acetylation mapping results
p53 was treated with 0.25 mM aspirin, digested with a protease and analyzed by LCMS/MS (Thermo LTQ) . Tryptic peptides (solid line) and a chymotryptic-tryptic double
digest (dashed line) covered 82% of the sequence. Mascot search allowed for variable
lysine acetylation and 2 missed trypsin cleavages. Sixteen tryptic peptides had blocked
trypsin cleavages at nine lysine sites with an acetyl modification. LC-MS/MS analysis of
untreated p53 did not reveal any lysine acetylation.
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Figure 3.7 MS/MS fragmentation spectra show an acetyl modification of Lys-120
MS full spectrum tolerance was 1.5 Da and MS/MS ion tolerances were 0.8 Da for this and
all subsequent figures. The Mascot ion score was 56, Expect value equaled 1.3×10-6, and
MS parent ion error was 1.81 Da. The mapped acetylated lysine position (peptide position
#10) is supported by b8, b9, b10, y12, and y13 ions that hit or flank the PTM position
(circled in blue), which also is an internal lysine that is possibly blocked in trypsin cleavage
by the acetyl group: LGFLHSGTAK*SVTCTYSPALNK.
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Figure 3.8 MS/MS fragmentation spectra show an acetyl modification of Lys-132
The Mascot ion score = 84, Expect = 4.4×10-9, and MS parent ion error was 1.45 Da. The
mapped acetylated lysine position (peptide position #12) is supported by b10, b12, b13, y7,
y8, and y9 ions that hit or flank the PTM position (circled in blue), which is also a blocked
trypsin cleavage site. The following unmodified peptides are present in the LC-MS/MS
run: SVTCTYSPALNK and MFCQLAK, suggesting that acetylation blocked trypsin
cleavage of this peptide SVTCTYSPALNK*MFCQLAK.
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Figure 3.9 MS/MS fragmentation spectra show an acetyl modification of Lys-139
The Mascot ion score = 100, Expect = 7.6×10-10, and MS parent ion error was 1.23 Da. The
mapped acetylated lysine position (peptide position #7) is supported by b7, b8, b9 (see
inset), and y17 ions that hit or flank the PTM position (circled in blue), which is also a
blocked trypsin cleavage site. The following unmodified peptides are present in the LCMS/MS run: MFCQLAK and TCPVQLWVDSTPPPGTR, suggesting acetylation blocked
trypsin cleavage of this peptide MFCQLAK*TCPVQLWVDSTPPPGTR.
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Figure 3.10 MS/MS fragmentation spectra show an acetyl modification of Lys-292
The Mascot ion score = 34, Expect = 4.6×10-4, and MS parent ion error was 0.60 Da. The
mapped acetylated lysine position (peptide position #1) is supported by the difference
between the parent ion mass with the acetyl group on the N-terminal lysine and by the
fragment ions b2 and y13 that flank the PTM position (circled in blue), which is also a
blocked trypsin cleavage site: K*GEPHHELPPGSTK.

Figure 3.11 MS/MS fragmentation spectra show an acetyl modification of Lys-305
The Mascot ion score = 28, Expect = 2.5×10-3, and MS parent ion error was 1.04 Da. The
mapped acetylated lysine position (peptide position #15) is supported by double charged
ions b++14, b++15 (inset on top), and y2 ions that hit or flank the PTM position (circled in
blue), which is also a blocked trypsin cleavage site: KKGEPHHELPPGSTK*R.
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Figure 3.12 MS/MS fragmentation spectra show an acetyl modification of Lys-319
The Mascot ion score = 71, Expect = 1.3×10-7, and MS parent ion error was 0.49 Da. The
mapped acetylated lysine position (peptide position #13) is supported by b13, y2, and y3
ions that hit or flank the PTM position (circled in blue), which is also a blocked trypsin
cleavage site. The following unmodified peptides are present in the LC-MS/MS run:
ALPNNTSSSPQPK, suggesting that acetylation (*) blocked trypsin cleavage of this
peptide: ALPNNTSSSPQPK*K.

Figure 3.13 MS/MS fragmentation spectra show an acetyl modification of Lys-321
The Mascot ion score = 71, Expect = 7.2×10-8, and MS parent ion error was 0.71 Da. The
mapped acetylated lysine position (peptide position #1) is supported by the parent ion mass,
the b2, and y12 ions that hit or flank the PTM position (circled in blue), which is also a
blocked trypsin cleavage site: K*PLDGEYFTLQIR.
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3.3

Discussion
In this chapter, we demonstrated that exposure of cells to aspirin acetylated p53 in

HCT 116 cells containing wild-type p53 and HT-29 cells harboring mutant p53
(R273H)139. In both cell lines, acetylated p53 was localized to the nucleus confirming the
role p53 as a TF. Mass spectrometry of the acetylated wild-type rp53 showed that aspirin
acetylated a total of 9 lysine residues. These include: K120, K132, K139, K164, and K292
in the DNA binding domain, and K305, K319, K320, and K321 in the nuclear localization
signal (NLS) domain. Immunoblotting experiments showed that K382 in the C-terminal
regulatory domain is also acetylated by aspirin. The acetylation at K382 was not detected
in the MS analysis, this may be due to the less abundance of the modified peptide in the
trypsin /chymotrypsin digest, or related to the stability of the modification during MS
analysis145. It is important to note that in a previous study, our group reported the
acetylation of p53 at K382 in MDA-MB-231 cells using an antibody specific for acetylated
K38235. Based on the data obtained from MS and immunoblotting in this study, we
conclude that aspirin acetylated a total of 10 lysine residues on p53 (see Table 3.1, page
53). Molecular modeling of rp53 (NCBI accession no: NP_000537.3) showed that all
aspirin acetylated lysine residues are surface exposed /solvent accessible. The ability of
aspirin to acetylate p53 in vitro also suggest that, it is a non-enzymatic chemical reaction,
consistent with its ability to acetylate a number of other proteins in vitro as has been
demonstrated in a previous study26.
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Figure 3.14 The 3D space model of recombinant p53 (NP_000537.3)
In this figure, the locations of aspirin acetylated lysines are marked in blue (K120, K132,
K139, K164, K292, K305, K319, K320, K321, and K382).

Aspirin is mainly absorbed intact in the GI tract, and later hydrolyzed to acetate and
salicylate ions in the liver and plasma. Plasma concentration of intact aspirin following
administration of analgesic and anti-inflammatory doses can range from 30 to 150 µM4.
However, a similar estimation of intact aspirin in the GI tract has not been reported. One
report suggested that, in vivo, when aspirin is ingested, the stomach /GI cells are likely to
get exposed to high concentrations of aspirin (up to 30 mM) with standard analgesic doses
(2 standard 300 mg tablets)146. In the present study, we used aspirin at a concentration
ranging from 0.1 mM to 2.5 mM to demonstrate the ability of aspirin to acetylate p53 and
induce p21CIP1 in HCT 116 and HT-29 cells. The higher concentrations of aspirin (1-2.5
mM) used in this study using the cell culture experiments may have greater significance to
the GI tissue as GI cells are likely to get exposed to higher concentrations of the drug upon
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oral ingestion in vivo. The concentration around 0.1 mM maybe more relevant to the distal
tissues, as these tissue types are likely to get exposed to lower concentrations of intact
aspirin. Studies show that aspirin is more effective in decreasing the incidence of colon
cancer compared to cancer in the distal tissues such as breast, ovary, lung and skin (see
Table 1.1, page 8)4,41. It is possible that greater cancer risk reduction observed in the GI
tract may be related to increased acetylation of proteins including p53. We are confident
that our studies represent therapeutically relevant doses of aspirin demonstrating strong
translational relevance to the GI tissues.
Acetylation of p53 at lysines has been shown to affect its turnover /stability, by
competing with other lysine-dependent modifications that have inhibitory effects on p53
such as ubiquitination98. Our observation that aspirin can acetylate 10 lysines at different
domains in p53 suggests that these modifications may affect p53 conformation, localization
or functional activity. p53 contains a total of 20 lysine residues in its 393 amino acid
sequence. Of these, 10 lysine residues (K120, K164, K305, K320, K370, K372, K373,
K381, K382, and K386) are naturally acetylated by acetyltransferases in response to
various stresses92. The significance of p53 acetylation is two-fold: 1) it promotes p53
stabilization by excluding ubiquitination on the same site; 2) it recruits cofactors for the
promoter-specific activation of target genes92,97,147. It is interesting to note that 5 of the
lysines acetylated by aspirin (K120, K164, K305, K320, and K382) are also the target of
acetylation by cellular acetyltransferases (see Table 3.1, page 53). Among these, K382 is
present in the C-terminal domain. C-terminal domain contains 6 lysines (K370, K372,
K373, K381, K382, and K386), all of which are targeted for ubiquitination by MDM2 (an
E3 ubiquitin-protein ligase), as well as acetylation by CBP/p300 acetyltransferases (see
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Table 3.1, page 53). In normal cells (under no or low genotoxic conditions), ubiquitination
of these 6 C-terminal lysines in p53 causes its degradation; however, exposure of cells to
genotoxic agents leads to acetylation and stabilization, and also an increase in DNA
binding activity99,100. It is possible that aspirin-mediated acetylation of K382 in the Cterminal domain may stabilize p53, leading to increased DNA binding activity and target
gene expression. This view is further supported by a previous report by our group that
exposure of MDA-MB-231 breast cancer cells to aspirin increased acetylation of p53 at
K382, and was associated with an increase in DNA binding activity and expression of
p21CIP1 and Bax35.
We observed that aspirin also acetylated K305 and K320 which are localized to the
NLS domain, and K120 and K164 in the DNA binding domain (see Table 3.1, page 53).
Reports in literature showed that acetylation at these sites by cellular acetyltransferases
increases sequence-specific DNA binding in the promoters of p53 target genes. For
example, according to a previously published report, acetylation of K320 by the
P300/CBP-associated factor (PCAF) increased interactions of p53 with the high-affinity
p21CIP1 promoters148. In another study, Sykes et al showed that hMOF and TIP60
acetyltransferase-mediated K120 acetylation is important for the induction of proapoptotic
Bax and PUMA genes149. These reports when combined with our MS study, raise the
intriguing possibility that acetylation of K120 and K320 by aspirin may increase sequencespecific DNA binding leading to the induction of p21CIP1 and Bax gene expression. The
MS analysis also identified 5 unique lysine residues in recombinant p53 as acetylation
targets of aspirin. These include: K132, K139, and K292, in the DNA binding domain and
K319 and K321 in the NLS domain (see Table 3.1, page 53). The significance of
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acetylation at these lysines is currently not known. It is possible that aspirin-mediated
chemical acetylation of p53 may shift the equilibrium of the enzymatic acetylation/
deacetylation process that occurs naturally in cells via acetyltransferases, bringing about
major changes in gene expression.
Although the contribution of the p53 pathway in aspirin’s anti-cancer effects has
not been studied till date, some reports in the literature, in addition to ours, supports such
a possibility. One report published in 2003 implicated p53 signaling in aspirin-mediated
apoptosis in OC2 human oral cancer cells150. They showed that aspirin exposure to OC2
cells increased p53 levels, and this was associated with induction of p21CIP1 and Bax
expression. In a previous study, our group demonstrated that aspirin acetylated mutant p53
(R280K) in MDA-MB-231 breast cancer cells35. In that study, our group reported that
aspirin increased p53 DNA binding activity and increased expression of two p53 target
genes: p21CIP1 and Bax. Interestingly, 2 recent reports by Huang et al137,138 again support
our finding that aspirin is capable of acetylating p53. In the first study, they demonstrated
the ability of phospho-aspirin, a derivative of aspirin, to acetylate wild-type p53 in MCF7, and mutant p53 at K373 in T47D breast cancer cells137. T47D breast cancer cells harbor
a mutant p53 (L194F)139. In a second study, they showed that exposure of MDA-MB-231
cells harboring mutant p53 (R280K) to phospho-aspirin acetylated K373 and K38226.
According to Huang et al, acetylation of p53 disrupted its interaction with its repressor
MDM2, and this was associated with induction of p21CIP1 expression30. These results
further support the view that chemical-acetylation of p53 by aspirin or phospho-aspirin,
may indeed cause its activation leading to induction of target gene expression.
Our observation that aspirin acetylates wild-type p53 in HCT 116 cells as well as
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mutant p53 in HT-29 cells has important implications for both cancer prevention and
cancer therapy. It is to be noted that nearly 50% of all tumors contain a mutated p53 with
varied levels of inactivation104,139 and nearly 80% of these mutations are miss-sense type
mutations found mainly in the DNA-binding domain (aa 98-292)94. Among these, some
lead to partial inactivation, whereas others are more lethal, and some acquire gain of
function, favoring cancer cell growth139,151. Due to the presence of high frequency of p53
mutations leading to a loss of its tumor suppressor functions, there have been attempts to
identify molecules capable of reactivating mutant p53 as a strategy to suppress tumor
growth105,152-154. One report showed that acetylation of mutant p53 by PCAF
acetyltransferase increased its DNA binding ability and growth suppressive activity140. The
HT-29 cancer cells harbor a mutant p53 (R273H), this is presenting in the DNA binding
domain, and this locus (R273) accounts for 6.7% of all the p53 mutation observed in cancer
patients102,103. Therefore, using aspirin, it may be also possible to restore the lost tumor
suppressor functions in mutant p53 through chemical acetylation.
Aspirin’s unique ability to acetylate proteins have been documented by our
group32,35 and recently by other investigators33,34; however, additional efforts are needed to
understand the effect of this post-translational modification on protein structure and
functions. p53 is one of the hundreds of proteins identified as the targets of aspirin in these
reports. Our observation that aspirin can acetylate wild-type and mutant p53 should be
explored in greater depth for its full potential as a drug in chemoprevention or
chemotherapy. Identification of aspirin acetylated target sites on p53 as reported in this
chapter, is an important step in this regard.
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Chapter 4. Aspirin Inhibits Glucose-6-Phosphate Dehydrogenase Activity in
HCT 116 Cells through Acetylation: Identification of Aspirin Acetylated Sites
This work was submitted to Molecular Medicine Reports, accepted.
4.1

Abstract
Glucose-6-phosphate dehydrogenase (G6PD) catalyzes the first reaction in the PPP

and generates ribose sugars required for nucleic acid synthesis, and NADPH important for
neutralization of oxidative stress. Expression of G6PD is elevated in many tumors such as
colon, breast and lung cancers and has been implicated in cancer cell growth. We
previously demonstrated that aspirin exposure to HCT 116 human colon cancer cells
caused acetylation of G6PD and this was associated with a decrease in its enzyme activity.
In the present study, we extended this observation to HT-29 colon cancer cells to compare
aspirin-mediated acetylation of G6PD and its activity between HCT 116 and HT-29 cells,
and also determined the aspirin’s acetylation targets on recombinant G6PD to get an insight
into the mechanisms of inhibition. Here we show that the extent of G6PD acetylation was
significantly higher in HCT 116 cells compared to HT-29 cells; accordingly, greater
reduction in G6PD enzyme activity was observed in HCT 116 cells. Mass spectrometry
analysis of the aspirin-acetylated G6PD (isoform a) revealed that aspirin acetylated a total
of 14 lysine residues, and these were dispersed throughout the length of the G6PD protein.
One of the important amino acid targets of aspirin included lysine 235 (K235, in isoform
a) and this corresponds to K205 in isoform b, which was previously identified important
for catalysis. Acetylation of G6PD at multiple sites including K235 (K205 in isoform b)
may mediate inhibition of G6PD activity and this may contribute to aspirin’s ability to
exert anti-cancer effects through decreased synthesis of ribose sugars and NADPH.
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4.2

Results
Our group previously demonstrated that that aspirin exposure to HCT 116 cells caused

acetylation of G6PD, and this was associated with a decrease in its enzyme activity.
Glucose-6-phosphate dehydrogenase is an important regulatory enzyme in the PPP, and
produces ribose-5-phosphate essential for nucleic acid synthesis in the rapidly dividing
cells118,119. The observation that aspirin through acetylation inhibits G6PD activity
suggested that this may contribute to its anti-cancer effects. In the present study, we
extended the earlier observations to HT-29 human colon cancer cells and compared aspirinmediated acetylation of G6PD and enzyme activity between HCT 116 and HT-29 cells.
G6PD assays were performed to compare the enzyme activity between HCT 116 and HT29 cells. Mass spectrometry analysis was performed on the recombinant G6PD isoform a,
to identify aspirin acetylated lysine sites to gain insight into the mechanism of inhibition
of enzyme activity.
4.2.1

Correlation between G6PD acetylation status and activity in HCT 116 and
HT-29 cells
To compare the levels of aspirin-mediated G6PD acetylation between HCT 116 and

HT-29 cells, cells were left untreated or treated with aspirin at two different concentrations
(0.5 mM and 2.5 mM) for 24 h, and the lysates were immune-precipitated with anti-acetyl
lysine antibody, and immunoblotted with anti-G6PD antibody. Figure 4.1 A demonstrates
that aspirin-induced acetylation of G6PD was detected at 0.5 mM; however, significantly
increased levels were detected at 2.5 mM concentration. In contrast, in HT-29 cells, G6PD
acetylation was not observed at all at 0.5 mM; but, barely detected at 2.5 mM (see Figure
4.1 B). Figure 4.1 C and D show that both isoforms of G6PD (isoforms a and b) were
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detected in HCT 116 and HT-29 cells. We then assayed for the G6PD activity in the lysates
prepared from both HCT 116 and HT-29 cells. Figure 4.2 demonstrates that aspirin
progressively inhibited G6PD activity in HCT 116 cells beginning at 0.5 mM; however,
much lesser inhibition was observed in HT-29 cells. This suggests that, aspirin-mediated
acetylation may lead to inhibition of G6PD activity within cellular milieu.

Figure 4.1 Aspirin-mediated acetylation of G6PD is significantly greater in HCT 116
than in HT-29 cells
Sub-confluent cells were left untreated or treated with aspirin for 24 h, lysates prepared
and equal amounts of the protein were immunoprecipitated with rabbit anti-acetyl lysine
antibody conjugated to agarose. Proteins were eluted from the resins and immunoblotted
with anti-G6PD antibody. For C and D, the samples representing A and B were
immunoblotted with anti-G6PD antibody. These experiments were repeated three times.
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Figure 4.2 Effect of aspirin on G6PD activity in HCT 116 and HT-29 cells
Cells were cultured and left untreated or treated with aspirin for 24 h. One hundred µg of
the protein was used for the G6PD assay according to the prescribed protocol (Biovision
Inc). The reaction mixture was incubated at 37°C for 30 min, the absorbance measured at
450 nm. The G6PD activity was expressed as the percentage of control. These experiments
were repeated three times. The significance are compared to control, *:P<0.05, **: P<0.01,
***: P<0.001.
4.2.2

In vitro acetylation of recombinant G6PD protein by aspirin
Human G6PD enzyme (isoform a, long form) has a total 29 lysine residue in its 545

aa long sequence. To determine which of the lysines are targeted by aspirin, the
commercially obtained purified recombinant G6PD was acetylated with aspirin in vitro and
the product was subjected to MS analysis. For this, 5 µg of the purified G6PD protein was
incubated with 0.25 mM aspirin for 12 h, and an aliquot (5 ng) of the sample was first
analyzed by immunoblotting with anti-acetyl lysine antibody to ensure acetylation. Figure
4.3 A demonstrates that anti-acetyl antibodies prominently detected a 56 kDa protein in the
aspirin-treated conditions, but this was not detected in the untreated control.
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Figure 4.3 Mass spectrometry analysis of recombinant G6PD isoform a
A, In Vitro acetylation of recombinant G6PD by aspirin. For A, 5 ng of the in vitro
acetylated recombinant G6PD was immunoblotted with anti-acetyl lysing antibody and the
protein band was detected by ECL. B represents MS/MS fragmentation spectra showing an
acetyl modification of K235.

4.2.3

Identification of aspirin acetylated sites on recombinant G6PD
An aliquot of the in vitro acetylated G6PD (isoform a) representing the blots in

Figure 4.3 A was subjected to MS analysis for the identification of acetylation sites. Based
on the MS analysis (see Figure 4.3 B; Figure 4.6 to Figure 4.17 and Table 4.2, page 74),
we identified a total of 14 lysine residues (K77, K112, K119, K201, K235, K390, K396,
K416, K438, K459, K462, K527, K538, K544) as target of aspirin-mediated acetylation
(see Table 4.1). The peptide digests covered 86% of the total G6PD sequence. It is
interesting to note the lysine at position 235 (K235) (corresponds to K205 in isoform b of
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G6PD) located in the active site of the enzyme within the evolutionarily conserved peptide
(RIDHYLGK; aa 228-235), is acetylated by aspirin. Lysine 205 (in isoform b) has been
previously demonstrated to be important for catalysis121. It is likely that acetylation of this
residue is responsible for the observed decrease in G6PD activity in HCT 116 cells.
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Table 4.1 Location of aspirin acetylated lysine residues identified in this study and
the naturally acetylated lysines on G6PD
Aspirin acetylated lysine sites

Corresponding lysine sites in

Naturally

in isoform a (long)

isoform b (short)

acetylated sites

K77

K47

K112

K82

K119

K89

K89

K201

K171

K171

K235

K205 *

K390

K360

K396

K366

K416

K386

K386
K403

K438

K408

K459

K429

K462

K432

K432

K527

K497

K497

K538

K508

K544

K514

K514

Note that aspirin mediated lysine acetylation targets included 6 of the 7 naturally
acetylated lysine residues. *: the K205 was identified as important for catalysis121,122.

Molecular modeling of recombinant G6PD (NCBI accession no: NP_000393) showed
that most of the aspirin acetylated lysine residues are surface exposed /solvent accessible
(see Figure 4.4 for isoform a and Figure 4.5 for isoform b). The ability of aspirin to
acetylate G6PD in vitro also suggests that, it is a non-enzymatic chemical reaction,
consistent with its ability to acetylate a number of other proteins in-vitro26.
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Figure 4.4 The 3D space model of recombinant G6PD isoform a (NP_000393)
The locations of aspirin acetylated lysine are marked in blue.

Figure 4.5 The 3D space model of recombinant G6PD isoform b (NP_001035810.1)
The locations of aspirin acetylated lysine are marked in blue.
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Table 4.2 Acetylated peptides identified from G6PD after aspirin treatment (MS)
Acetylated
position

Tryptic peptides

Mascot

Chymotryptic

score

peptides

Score

77

K*IYPTIWWLFR

43

AKKK*IYPTIW

33

112

K*QSEPFFK

31

TVADIRK*QSEPF

25

119

KQSEPFFK*

FK*ATPEEKL

31

K*ATPEEKL

31
26

37

201

IIVEK*PFGR

56

NRIIVEK*PF

235

IDHYLGK*

33

LGK*EMVQNL

IDHYLGK*EMVQNLMVLR

17

390

CGK*ALNER

46

396

(tryptic peptide is too small)

416

LQFHDVAGDIFHQQCK*R

24

438

K*PGMFFNPEESELDLTYGNR

47

459
462

NVK*LPDAYER

22

527

GPTEADELMK*R

78

GPTEADELMK*R

61

VGFQYEGTYK*WVNPHK

50

538
544

26

NERK*AEVRLQF

26

HQQCK*RNEL

27

K*NVKLPDAY

28

K*NVKLPDAYERL

43

KWVNPHK*L

26
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Figure 4.6 MS/MS fragmentation spectra show an acetyl modification of Lys-77 in
G6PD
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Figure 4.7 MS/MS fragmentation spectra show an acetyl modification of Lys-112 in
G6PD

77

Figure 4.8 MS/MS fragmentation spectra show an acetyl modification of Lys-119 in
G6PD
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Figure 4.9 MS/MS fragmentation spectra show an acetyl modification of Lys-201 in
G6PD
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Figure 4.10 MS/MS fragmentation spectra show an acetyl modification of Lys-390 in
G6PD
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Figure 4.11 MS/MS fragmentation spectra show an acetyl modification of Lys-396 in
G6PD
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Figure 4.12 MS/MS fragmentation spectra show an acetyl modification of Lys-416 in
G6PD
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Figure 4.13 MS/MS fragmentation spectra show an acetyl modification of Lys-438 in
G6PD
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Figure 4.14 MS/MS fragmentation spectra show an acetyl modification of Lys-459 in
G6PD
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Figure 4.15 MS/MS fragmentation spectra show an acetyl modification of Lys-462 in
G6PD
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Figure 4.16 MS/MS fragmentation spectra show an acetyl modification of Lys-527 in
G6PD
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Figure 4.17 MS/MS fragmentation spectra show an acetyl modification of Lys-538 in
G6PD

4.3

Discussion
Pentose phosphate pathway generates ribose sugars required for nucleic acid

synthesis and thus plays a major role in rapidly growing cancer cells. We previously
reported that aspirin acetylates G6PD in HCT 116 cells and this was associated with a
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decrease in its enzyme activity; however, the mechanism leading to this inhibition was not
clearly identified32. The goal of the present study was two-fold: 1) to compare aspirinmediated G6PD acetylation and enzyme activity between HCT 116 and HT-29 cells; 2)
identify the aspirin-mediated acetylation targets in the recombinant G6PD. Here we
demonstrated that aspirin exposure to HCT 116 cells caused a greater acetylation of G6PD
than in HT-29 cells; accordingly, increased inhibition of G6PD activity was also observed
in HCT 116 cells. Although acetylated G6PD levels were lower in HT-29 cells, the G6PD
protein levels (both isoform a and b) were similar in both HCT 116 and HT-29 cells. The
decreased levels of G6PD acetylation in HT-29 cells may be related to a lower aspirin
uptake, or more rapid hydrolysis of aspirin within the cells due to the action of esterases.
Through MS analysis of the in vitro acetylated recombinant G6PD (isoform a), we
identified a total of 14 lysine residues (K77, K112, K119, K201, K235, K390, K396, K416,
K438, K459, K462, K527, K538, K544) as targets of aspirin-mediated acetylation(see
Table 4.1, page 72). These sites are dispersed throughout the length of G6PD protein and
are located in both the NADP binding (aa 65-240) and the C-terminal domains (aa 242536)155. Our study suggests that, in some cancer cell lines, aspirin may cause a direct
inhibition of G6PD activity by modifying the protein via acetylation; and this potentially
contributes to the reduced synthesis of ribose sugars and NADPH in cancer cells.
Glucose-6-phosphate dehydrogenase has been shown to undergo posttranslational
modifications involving both phosphorylation and acetylation, affecting its enzyme
activity. The 7 naturally occurring acetylation sites on G6PD has been discussed in the
Introduction (see section 1.10, page 22). Comparison of the naturally acetylated sites with
aspirin-acetylated sites shows that, 6 of the 7 sites are common: K119, K201, K416, K462,
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K527, and K544 (see Table 4.1, page 72). One of the more prominent findings in this study
is the acetylation of K235 by aspirin in G6PD isoform a, which corresponds to K205 in
isoform b. K205 in isoform b was demonstrated to be part of the active site of the enzyme,
and important in catalysis121. The K205 is located within the highly conserved peptide
RIDHYLGK (residues 198-205, a single letter amino acid code in isoform b)123.
Interestingly, in an earlier study, it was shown that exposure of purified yeast G6PD to
aspirin caused acetylation of a lysine within the G6PD peptide sequence IDHYLGK (aa
185-191), and this resulted in the inactivation of the enzyme activity156. These previous
reports121,156 along with our present finding suggest that acetylation of this critical lysine
(K205 in isoform b, and 235 in isoform a) important for catalysis may affect substrate
binding (glucose-6-phosphate) and contribute to the aspirin-mediated inhibition of G6PD
activity observed in HCT 116 and HT-29 cells. Alternatively, acetylation at other lysines
may affect the affinity of NADP binding to G6PD, or simply may affect the dimer/tetramer
formation required for keeping the enzyme in the active configuration. Molecular modeling
on G6PD isoform a suggested that most of the aspirin acetylated lysines are surface
exposed/solvent accessible (see Figure 4.4, page 73). Similar molecular modeling on
isoform b suggested that the corresponding amino acids (including K205 in the active site)
are also surface exposed (isoform b, see Figure 4.5, page 73).
In a recent study by Wang et al.122, it was shown that acetylation at K403 (in G6PD
isoform b) mediated by cellular lysine acetyltransferases negatively regulates the enzyme
activity. They demonstrated that K403 acetylated G6PD is incapable of forming active
dimers and displays a complete loss of activity. The K403 lysine in isoform b corresponds
to K433 in isoform a, and in our MS study, this lysine was not identified as a target of
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aspirin. However, other lysine residues in close proximity, such as K416 and K438 were
acetylated upon treatment with aspirin.
Our observation that aspirin acetylates G6PD, and this is associated with a decreased
enzyme activity, potentially due to the modification of a lysine within the highly conserved
peptide RIDHYLGK, is an important finding in the context of known role for G6PD in
cancer cell growth. Elevated expression of G6PD has been observed in multiple cancers
including breast, colon, endometrial, cervical, prostatic and lung cancers118,119,124-127. This
enzyme through a sequential reaction, generates NADPH and ribose-5-phosphates,
important for cancer cell growth. Due to its important role in cancer development, and
increased expression in cancers, it is argued that G6PD is a potential therapeutic target for
cancer treatment119. Based on our findings in HCT 116 cells, and the acetylation of lysine
at 235 in the isoform a (equivalent to K205 in the isoform b), it is likely that aspirin may
inhibit G6PD activity in other cancer cell types; and thus, may contribute to decreased
cancer cell growth through reduced synthesis of ribose sugars and NADPH.
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Chapter 5. Aspirin and Salicylic Acid Decrease c-Myc Expression in Cancer
Cells: a Potential Role in Chemoprevention
This work has been published in Tumour Biol. (2015). DOI: 10.1007/s13277-015-3959-0
5.1

Abstract
Epidemiological studies have demonstrated a significant correlation between

regular aspirin use and reduced colon cancer incidence and mortality; however, the
pathways by which it exerts its anticancer effects are still not fully explored. We
hypothesized that aspirin’s anti-cancer effect may occur through down-regulation of c-Myc
gene expression. Here, we demonstrate that aspirin and its primary metabolite, salicylic
acid, decrease the c-Myc protein levels in human HCT 116 colon and in few other cancer
cell lines. In total cell lysates, both drugs decreased the levels of c-Myc in a concentrationdependent fashion. Greater inhibition was observed in the nucleus than the cytoplasm, and
immunofluorescence studies confirmed these observations. Pre-treatment of cells with
lactacystin, a proteasome inhibitor, partially prevented the down-regulatory effect of both
aspirin and salicylic acid, suggesting that 26S proteasomal pathway is involved. Both drugs
failed to decrease exogenously expressed DDK-tagged c-Myc protein levels; however,
under the same conditions, the endogenous c-Myc protein levels were down-regulated.
Northern blot analysis showed that both drugs caused a decrease in c-Myc mRNA levels
in a concentration-dependent fashion. High-Performance Liquid Chromatography analysis
showed that aspirin taken up by cells was rapidly metabolized to salicylic acid, suggesting
that aspirin’s inhibitory effect on c-Myc may occur through formation of salicylic acid.
Our result suggests that salicylic acid regulates c-Myc level at both transcriptional and
post-transcription levels. Inhibition of c-Myc may represent an important pathway by

91

which aspirin exerts its anti-cancer effect and decrease the occurrence of cancer in
epithelial tissues.
5.2

Results
c-Myc is a TF that controls nearly 15% of the expression of all genes109, it is

mutated or amplified in nearly 20% of all cancers leading to its abnormal expression. Since
deregulated expression of c-Myc is a hallmark of cancer, we considered the possibility that
aspirin’s anti-cancer effect may involve downregulation of c-Myc mRNA or protein levels,
or both. In this chapter, we investigated the effect of aspirin and its primary metabolite
salicylic acid, on c-Myc protein and mRNA levels in HCT 116 colon cancer cells. Studies
were also performed on the effect of aspirin and salicylic acid on 4 other cancer cell lines:
HT-29 (colon), MDA-MB-231 (breast), NCI-H226 (lung) and SW480 (colon) cells.
5.2.1

Aspirin and salicylic acid decrease growth rate in HCT 116 cells at
concentrations ranging from 0.25 mM to 2.5 mM

Previous studies have shown that treatment of cells with aspirin-induced a profound
concentration-dependent reduction in the cell proliferation rate in HCT 116 cells157,158.
Another study showed that salicylic acid at concentrations ranging from 2.5-10 mM
inhibited HCT 116 cell growth83; however, the effect of these drugs at lower concentrations
was not reported. To evaluate the effect of aspirin and salicylic acid on the proliferation
rate, HCT 116 cells were treated separately with both drugs at different concentrations 0.25
to 2.5 mM for 48h, and counted and the viability of cells was determined by trypan blue
exclusion. We observed that aspirin and salicylic acid progressively reduced the cell
numbers compared to control at all concentration tested from 0.25 mM to 2.5 mM, without
affecting cell viability (see Figure 5.1). In these experiments, more than 95% of cells were
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viable in the control and treated conditions, the number of dead cells was less than 5% in
all groups. This suggests that treatment of cells with drugs for 48 h does not cause cell
death, but reduces the cell number, suggesting that aspirin and salicylic acid inhibit cell
proliferation.

Viability

Figure 5.1 Dose-dependent effect of aspirin and salicylic acid on the growth rates of
HCT 116 cell
HCT 116 cells were seeded at 50% confluency and treated with different concentrations of
aspirin and salicylic acid and cells counted, viability determined as described in the
materials and methods.

5.2.2

Aspirin and salicylic acid decrease c-Myc protein levels in HCT 116 cells
To determine whether aspirin and salicylic acid decrease c-Myc levels, cells were

left untreated or treated with aspirin or salicylic acid at various concentrations for 24 h.
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Cell lysates were prepared and immunoblotted with anti-c-Myc antibody. Figure 5.2 A/C
and B/D demonstrates that significant decrease in c-Myc levels was observed with both
drugs at 2 mM and 2.5 mM concentrations. At lower concentrations of the drugs, the
observed decreases in c-Myc in the total cell lysates were marginal. Reprobing the blots
with anti-β-actin antibody showed that all lanes contained equal amounts of β-actin protein.

Figure 5.2 Aspirin and salicylic acid down-regulate c-Myc protein levels in HCT 116
cells
A, Anti c-Myc antibody immunoblot of proteins from aspirin-treated cells; lower panel
represents the anti β-actin antibody immunoblot; B, Anti c-Myc antibody immunoblot of
proteins from salicylic acid treated cells; the lower panel represents its anti-β-actin
antibody immunoblot. C and D, respectively represent quantification of the intensity of the
bands in blot A and B, expressed as a percentage of controls.
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Continued Figure 5.2, E, anti-c-Myc antibody immunoblot of proteins isolated from
nucleus and cytoplasm of aspirin-treated cells; the lower panel represents the anti β-actin
antibody immunoblot. F, anti-c-Myc antibody immunoblot of proteins isolated from
nucleus and cytoplasm of salicylic acid treated cells; the lower panel represents the anti βactin antibody immunoblot. G and H respectively represent quantification of the intensity
of the band in blot E and F, expressed as a percentage of controls.

5.2.3

Aspirin and salicylic acid-mediated c-Myc decrease is more pronounced in
the nucleus
To investigate the effect of aspirin and salicylic acid on the c-Myc levels in the

cytoplasm and nuclear compartments, cells were left untreated, or treated with aspirin and
salicylic acid at 0.5 mM or 2.5 mM for 24h, nuclear and cytoplasmic proteins isolated. The
proteins were analyzed by immunoblotting with the c-Myc antibody. Aspirin (Figure 5.2
E) and salicylic acid (Figure 5.2 F) both decrease the nuclear c-Myc levels beginning at
0.5 mM; however, in the cytoplasmic fraction, the decrease was observed only at higher
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concentrations (2.5 mM). This was further confirmed in immunofluorescence studies,
using anti-c-Myc antibody followed by detection with Alexa Flour 488-labeled secondary
antibody. Figure 5.3 demonstrates that exposure of cells to aspirin reduced the c-Myc levels
(Figure 5.3 B) significantly compared to untreated controls (Figure 5.3 A). Figure 5.3 C
and D represent the DAPI stained nuclei of untreated and treated cells, respectively. Upon
overlapping of the Alexa Flour 488 and DAPI stained images, it is clear that almost all of
the detected c-Myc was located in the nucleus (Figure 5.3 E and F). Similarly, treatment
with salicylic acid also reduced the c-Myc levels mainly in the nucleus (Figure 5.3 G-L).

Figure 5.3 Immunofluorescence studies show that aspirin and salicylic acid decrease
nuclear c-Myc levels in HCT 116 cells
The top panel shows immunofluorescence of c-Myc expression detected using the anti-cMyc antibody. The middle panel shows nuclear staining with DAPI. The lower panel shows
overlapped images of the top and middle panels. Cells were left untreated (A and G) or
treated with aspirin (B) or salicylic acid (H) and immunofluorescence carried out as
described in the methods. Images of cells were acquired using a Zeiss Axio Imager A1
microscope at a magnification of 40X.
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5.2.4

Lactacystin partially prevents aspirin and salicylic acid-mediated decrease in
c-Myc protein levels
c-Myc naturally undergoes degradation via a ubiquitin-proteasomal pathway in the

nucleus112. To determine a role for the proteasomal pathway, we tested the ability of
lactacystin, a 26S proteasomal inhibitor, to prevent the aspirin and salicylic acid-mediated
decrease in c-Myc levels. Cells were left untreated or first treated with lactacystin (10 µM)
for 1h, and then aspirin and salicylic acid (2.5 mM) were added for 24h. Cell lysates were
prepared and immunoblotted with anti-c-Myc antibody. Figure 5.4 A demonstrates that
lactacystin partially prevented the degradation of c-Myc level caused by aspirin and
salicylic acid. Quantification of these bands showed that aspirin and salicylic acid
decreased the c-Myc levels by 47% and 65% respectively (Figure 5.4 C). Lactacystin
treatment alone stabilized the c-Myc protein levels; it was 3-fold higher compared to
untreated control. However, in the presence of lactacystin, aspirin decreased c-Myc levels
by 40%, and salicylic acid decreased its levels by 41%, which suggests that, 26S
proteasomes are at least in part involved in aspirin and salicylic acid’s down-regulatory
effects on c-Myc.
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Figure 5.4 Effect of lactacystin (A) and calpeptin (D) on the ability of aspirin and
salicylic acid to decrease c-Myc protein levels in HCT 116 cells
A, shows that lactacystin partially prevents the down-regulatory effect of aspirin and
salicylic acid on c-Myc protein levels. D, shows that calpeptin is unable to prevent the
down-regulatory effect of aspirin and salicylic acid on c-Myc protein levels. Lactacystin
and calpeptin were pretreated for 1 h before treatment with aspirin and salicylic acid
treatment for 24h. A and D represent anti-c-Myc antibody immunoblots, B and E represent
anti-β-actin antibody immunoblots. C and F, represent quantification of the intensities of
the bands in blot A and D respectively. The numbers on top indicate the intensities of bands
expressed as a percentage of controls, underlined numbers indicate intensities of bands in
percentages in the last 3 lanes in A and D. Asp, aspirin; Sal, salicylic acid; Lac, lactacystin;
Cal, calpeptin.

5.2.5

Calpeptin did not prevent aspirin or salicylic acid-mediated c-Myc decrease
It was reported that calcium-dependent proteases belonging to the calpain family

could proteolytically cleave c-Myc159. Therefore, we investigated the ability of calpeptin
(10 µM) an inhibitor of calpain I and II to prevent the down-regulatory effect of aspirin

98

(2.5 mM) and salicylic acid (2.5 mM) on c-Myc levels. Cells were left untreated or first
treated with calpeptin for 1h, and then aspirin and salicylic acid were added for 24 h.
Lysates were prepared and immunoblotted with anti-c-Myc antibody. Figure 5.4 D and F
demonstrates that pretreatment with calpeptin did not prevent the ability of both drugs to
decrease c-Myc levels, suggesting that calpains are not involved in the down-regulatory
effect.
5.2.6

Effect of aspirin and salicylic acid on DDK-tagged exogenously expressed
c-Myc protein levels
To investigate whether the down-regulatory effect of aspirin and salicylic acid

occurs independent of nuclear transcriptional regulation, we determined the ability of both
drugs to decrease the exogenously expressed DDK-tagged c-Myc protein. HCT 116 cells
were left untransfected or transfected with DDK-tagged full-length c-Myc cDNA cloned
in the pCMV6 vector. The expression of the c-Myc DNA in this plasmid is directly under
the control of a CMV promoter. After transfections, cells were incubated for 24 h to allow
for the expression DDK-tagged c-Myc. Following this, cells were either left untreated or
treated with drugs at concentrations of 2.5 mM for 24 h. Cell lysates were prepared and
immunoblotted with anti-DDK or anti-c-Myc antibodies. Figure 5.5 A demonstrates antiDDK antibody detected the expression of the DDK-tagged c-Myc protein in transfected
cells (lane 4). Interestingly, treatment with aspirin or salicylic acid failed to inhibit the
DDK-tagged c-Myc (lanes 5 and 6). Reprobing the blot of Figure 5.5 A with β-actin
antibody showed equal amounts of the protein in all lanes (Figure 5.5 B). When the samples
were immunoblotted with anti-c-Myc antibody, the levels of exogenously expressed, DDK
tagged c-Myc protein was unchanged after aspirin or salicylic acid treatment (Figure 5.5
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C, lanes 5 and 6), consistent with the results obtained in Figure 5.5 A, lanes 5 and 6. Longer
exposure of the same blot (Figure 5.5 D), showed that the endogenous c-Myc levels were
significantly decreased in both untransfected (lanes 2 and 3) and transfected cells (lanes 5
and 6) compared to untreated cells (lanes 1 and 4) following treatment with drugs. These
results show that aspirin and salicylic acid selectively caused a decrease in the endogenous
c-Myc without affecting the exogenously expressed c-Myc.

Figure 5.5 Effect of aspirin and salicylic acid on the exogenously expressed DDK
tagged c-Myc protein levels.
Transfection studies were performed as described in the text. A, Anti-DDK antibody
immunoblot; B, anti-β-actin antibody immunoblot; C and D, respectively represent shorter
and longer exposures of anti-c-Myc antibody immunoblots. E, anti-β-actin antibody
immunoblot.

5.2.7

Aspirin and salicylic acid decrease the c-Myc mRNA levels
To gain insight into the mechanism by which aspirin and salicylic acid

downregulate c-Myc protein levels, we determined if exposure of the cells to these drugs
would cause a decrease in the c-Myc mRNA levels. Cells were left untreated or treated
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with aspirin or salicylic acid at 0.5 and 2.5 mM concentrations for 24 h; total RNA was
prepared and analyzed for c-Myc mRNA levels in Northern blots. Figure 5.6 A
demonstrates that in the untreated control cells, abundant c-Myc mRNA was detected; both
aspirin and salicylic acid caused a significant decrease in c-Myc RNA levels in a dosedependent fashion starting from 0.5 mM. Quantification of the intensities of the c-Myc
mRNA levels revealed that salicylic acid is more effective than aspirin (see Figure 5.6 C).
Figure 5.6 B shows the ethidium bromide stained pattern of the ribosomal 28S and 18S
RNA which shows equal RNA loading in all lanes. These results show that the observed
decrease in c-Myc protein levels following treatment with aspirin and salicylic acid is at
least in part due to decreased c-Myc mRNA levels within the cells.
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Figure 5.6 Aspirin and salicylic acid decrease c-Myc mRNA levels in a concentrationdependent fashion
For A, the blot was probed with 32P-labeled c-Myc cDNA; B, shows the ethidium bromide
stained 28S and 18S ribosomal RNA, showing equal loading of RNA. C, Quantification of
the band in blot A expressed as a percentage of control. Asp, aspirin; Sal, salicylic acid.
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5.2.8

Aspirin is rapidly taken up by cells and converted to salicylic acid
We hypothesized that the effect of aspirin on c-Myc is perhaps mediated by its

primary metabolite, salicylic acid as it is predicted to undergo hydrolysis in the medium,
or within the cells, by esterases. Therefore, we measured the intracellular levels of aspirin
and salicylic acid at 1 h following their addition to the cells. Cells were treated with aspirin
or salicylic acid at 2.5 mM for 1 h, harvested and lysed by sonication, and intracellular
aspirin and salicylic acid concentrations were measured by HPLC analysis. Figure 5.7 A
showed that very little intracellular aspirin was detected following treatment with 2.5 mM
aspirin after 1h; however, in these cells, the levels of salicylic acid was significantly higher
than the cells treated with 2.5 mM of salicylic acid. This suggests that aspirin is likely to
be taken up by the cells more efficiently than salicylic acid because of its structural
advantage and however, is rapidly metabolized to salicylic acid within the cells. Therefore,
the effect we observed in these cells on the down-regulation of c-Myc is likely due to
salicylic acid, the primary metabolite of aspirin.
5.2.9

Effect of aspirin and salicylic acid in other cancer cell lines
Having demonstrated the ability of aspirin and salicylic acid to decrease the c-Myc

protein in HCT 116 cells, we determined if this is also observed in other cancer cells. For
this, we chose to study c-Myc protein expression in the following cancer cell lines: SW480
(colon), NCI-H226 (lung), MDA-MB-231 (breast), HT-29 (colon), and PC-3 (prostate).
Cells were left untreated or treated with aspirin or salicylic acid at various concentrations,
total cell lysates or nuclear extracts prepared and immunoblotted with anti-c-Myc antibody.
We observed that salicylic acid caused a decrease in c-Myc protein levels in SW480 (Figure
5.7 B, Figure 5.8), NCI-H226 (Figure 5.7 C, Figure 5.8), and PC-3 cells (Figure 5.8).
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Interestingly, the inhibitory effect of salicylic acid was not observed in MDA-MB-231
(Figure 5.7 F) and HT-29 cells (Figure 5.7 G).

Figure 5.7 A, Aspirin is rapidly taken up by cells and hydrolyzed to salicylic acid
Cells were treated with 2.5 mM of aspirin and salicylic acid for 1h. Cells were washed,
lysed, and the drugs from intracellular fractions were extracted and quantified by HPLC.

104

Continued Figure 5.7, B and C, salicylic acid decreases c-Myc protein levels in SW480
colon and NCI-H226 lung cancer cell lines. D and E respectively represent the blots of B
and C reprobed with anti-β-actin antibody. F and G, respectively show that salicylic acid
does not decrease c-Myc levels in MDA-MB-231 breast and HT-29 colon cancer cells. H
and I, the blots in F and G were reprobed with the anti-PCNA antibody.
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Figure 5.8 Aspirin and salicylic acid decrease c-Myc protein levels in SW480, PC-3,
and NCI-H226 cells.

5.3

Discussion
In this chapter, we report that c-Myc is an important target of aspirin and salicylic

acid, as both drugs caused the down-regulation of c-Myc protein in multiple cancer cell
lines. This decrease in c-Myc protein levels appears to occur at least in part through a
lactacystin sensitive protease, suggesting that the 26S proteasomal pathway is involved.
The decrease was more pronounced in the nucleus than in the cytoplasm; in addition, in
the nucleus, it was observed at much lower concentrations (0.5 mM) than the cytoplasm,
or in total cell lysates. Importantly, both drugs decreased c-Myc mRNA levels in a
concentration-dependent fashion. We demonstrate this phenomenon at the physiologically
relevant concentrations of salicylic acid (0.5 mM to 2.5 mM), which according to the
literature, are achievable in the plasma with analgesic or anti-inflammatory aspirin doses
(see section 1.2, page 2)4. Therefore, our results have strong translational relevance.
The precise steps at which aspirin and salicylic acid affect the c-Myc gene
expression require further study. In normal cells, c-Myc gene expression is subject to
stringent regulation at multiple steps in its life. It is not transcribed in growth arrested
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quiescent cells. It is an “immediate early” gene, induced in response to growth factors and
the protein has a half-life of 20-30 min117,160. Studies show that c-Myc gene transcription
can be regulated at the level of initiation161, or elongation of the transcript during
transcription through the release of paused RNA polymerase II115. Once the c-Myc protein
is synthesized, it is post-translationally modified through phosphorylation, acetylation,
glycosylation, or ubiquitination, all of which affect its stability or functions160. The downregulation of the endogenous c-Myc protein levels observed with aspirin and salicylic acid
does not appear to be due to a direct degradation of c-Myc protein through proteolysis,
although we observed the involvement of a lactacystin sensitive protease in this process.
This is because, in cells transfected with DDK-tagged c-Myc plasmid, both drugs failed to
decrease the exogenously expressed c-Myc; however, under the same conditions, they
caused a reduction in the levels of endogenous c-Myc protein (see Figure 5.5 C and D,
page 99). The inability of aspirin and salicylic acid to decrease the exogenously expressed
c-Myc protein, as compared to the endogenous c-Myc, can be interpreted to suggest that
both drugs are likely to decrease the nuclear coded c-Myc gene transcription; however,
they do not decrease c-Myc gene transcription from the plasmid. The c-Myc gene in the
plasmid is directly under the control of a CMV promoter; whereas, the nuclear c-Myc is
subjected to regulation by TFs due the presence of many gene regulatory elements in the
genome. Thus, in aspirin and salicylic acid treated cells, any significant change in the levels
of c-Myc-specific upstream nuclear TFs would affect the nuclear c-Myc transcription;
while, transcription from the CMV promoter-driven c-Myc gene will not be affected. This
may lead to a decrease in the levels of nuclear coded c-Myc mRNA as compared to the
mRNA synthesis from the plasmid. In such a scenario, the endogenous c-Myc protein
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would be decreased while the synthesis and the levels of exogenous c-Myc protein would
not be affected.
The decrease in endogenous c-Myc protein was associated with a corresponding
decrease in the nuclear-coded c-Myc mRNA. In our Northern blot, we detected a 2.3 kb cMyc mRNA, consistent with the reported size in the literature161. It is unlikely that aspirin
and salicylic acid have any effect on RNA polymerase II, as levels of the exogenously
expressed c-Myc protein coded by the recombinant plasmid DNA remained unchanged.
Based on these results, we suggest that aspirin and salicylic acid downregulate c-Myc
mRNA levels by either decreasing the levels of a TF involved in c-Myc gene transcription,
or decreasing a protein that regulates c-Myc mRNA stability. In cells treated with drugs,
either of these (TF/proteins) may be degraded by the lactacystin sensitive protease, leading
to decreased c-Myc mRNA and protein levels. Thus, our results suggest that aspirin and
salicylic acid-mediated c-Myc downregulation is likely to occur at the transcriptional or
post-transcriptional level (see Figure 5.9).
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Figure 5.9 Diagrammatic representation showing the potential mode of downregulation of c-Myc by aspirin and salicylic acid.
We predict that aspirin via the formation of salicylic acid decreases the c-Myc mRNA at
the transcriptional or post-transcriptional level. Aspirin is rapidly taken up by the cells and
converted to salicylic acid by cellular esterases. Cells may also take up the salicylic acid
that is present in the medium formed by the hydrolysis of aspirin by serum esterases. Once
inside the cells, salicylic acid may bind to a c-Myc gene regulating TF and cause its
degradation via a lactacystin sensitive proteasomal pathway, leading to decreased mRNA
synthesis by RNA polymerase II. Alternatively, salicylic acid may bind and alter the
function of a c-Myc mRNA-binding protein (such as an mRNA stabilizing protein) leading
to its degradation by proteasomal pathway.

Once aspirin enters the cells, due to the presence of a reactive acetyl group, it can
acetylate a number of cellular proteins30,32; in addition, it is also subjected to hydrolysis to
give salicylic acid4,20,30. An aspirin-mediated decrease in c-Myc levels is likely to occur via
the formation of salicylic acid; because: 1) aspirin taken up by cells was rapidly hydrolyzed
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into salicylic (Figure 5.7 A); 2) in all experiments, salicylic acid mimicked the actions of
aspirin. In this study, the degree of c-Myc protein downregulation observed with aspirin
and salicylic acid varied according to the methods used to extract proteins. For example,
in total cell lysates, higher concentrations (2 and 2.5 mM) of the drugs were required to
observe the down-regulatory effects; however, in the nuclear fractions, this was observed
at much lower concentrations (0.5 mM). This difference could be related to the NaCl
concentrations used in the extraction buffers (for total cell lysate, 150 mM NaCl, and for
nuclear extraction 400 mM NaCl were used). Alternatively, this may simply reflect the
preferential localization of c-Myc to the nucleus as observed in immunofluorescence
experiments (see Figure 5.3, page 95)162.
It is not clear at this stage why down-regulation of c-Myc by aspirin and salicylic
acid is observed in selected cell lines (HCT 116, SW480 and NCI-H226); but not in others
(HT-29 and MDA-MB-231). This may be related to the level to which the c-Myc is
overexpressed in these cell lines as determined by the type of genetic alterations. In HT-29
cells, one study reported that c-Myc is deregulated, and ~4 to 6 copies of the gene is present
per cell163. c-Myc gene is also amplified in several breast cancer cells164, but it is not known
if it is amplified in MDA-MB-231 cells.
Aspirin’s ability to inhibit cell proliferation and induce cell cycle arrest has been
documented in the literature in many cancer cell lines83,157,158,165,166. For example, in HCT
116 cells, aspirin induced G1 arrest leading to cell apoptosis157. In HT-29 cells, aspirin
increased the proportion of cells in the G0/G1 phase166. In our study, aspirin and salicylic
acid down-regulated c-Myc in HCT 116 cells, but not in HT-29 cells. This suggests that
while down-regulation of c-Myc may contribute to the anti-proliferating effect of aspirin
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in HCT 116 cells, other pathways may be involved in the growth arrest in HT-29 cells.
Our observation that aspirin and salicylic acid decrease c-Myc levels is an
important finding in the context of known roles for c-Myc in normal cellular functions as
well as in cancer development. In normal cells, it is activated in response to the mitogenic
stimulus, plays a key role in the regulation of cell growth and proliferation, differentiation,
and apoptosis117. c-Myc regulates ~4000 genes in the genome (~15%) through binding on
to Enhancer Box sequences109. Identified c-Myc targets include genes involved in
metabolism, protein biosynthesis, cell cycle regulation, cell adhesion and ribosomal
biogenesis109. c-Myc regulates their transcription by recruiting histone acetylases, basal
TFs, and DNA methyltransferases. Its regulated expression in normal cell contributes to
the orderly activation and suppression of target genes.
While controlled expression of c-Myc is important in normal cellular functions, it
is one of the most frequently activated oncogenes, and is estimated to be involved in 20%
of all human cancers, affecting about 100,000 USA cancer deaths per year109. c-Myc
contributes to the transformation of normal cells to cancer cells through uncontrolled
cellular growth and proliferation. During tumorigenesis, it influences cellular adhesion,
metabolism, angiogenesis and causes genomic instability, thus, it is a central driver in many
cancers. Its amplification and overexpression are associated with poor prognosis and
treatment outcome167. Due to its role in cancer development, it is suggested that the c-Myc
could be targeted to inhibit cancer cell growth116. Developing drugs to target c-Myc has
been a challenge, because it lacks an enzyme activity and is a TF116. In this context, our
finding that aspirin and salicylic acid down-regulate c-Myc protein and mRNA levels,
should initiate new thinking and research on this age-old drugs in cancer treatment.
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Chapter 6. Summary, Conclusions, Limitations and Future Directions
6.1

Summary and conclusions
Over the years, limited progress has been made in our understanding of how aspirin

decreases the occurrences of epithelial cancers; this is because, many of the early
investigators focused more on the COX-dependent pathways due to its pivotal role in
inflammation. COX-2 is one of the proteins overexpressed in the cancer tissue168. It is also
involved in the synthesis of prostaglandins, leading to inflammatory responses. A
functional link between chronic inflammation and cancer has been suspected: populationbased studies show that susceptibility to cancer increases when tissues are chronically
inflamed; and long-term use of NSAIDs reduces the risk of several cancers169,170.
Accumulating evidence in the literature suggest a role for aspirin in the prevention
of epithelial cancers; however, precise mechanisms responsible for its anti-cancer effect
are still being elucidated. Unlike many drugs that generally have single target or
mechanism of action, aspirin appears to have multiple targets and mechanisms of actions.
This has been a frustrating aspect of aspirin research, because the contributions of each of
these targets to its anticancer effects have not been fully determined. Hence, a detailed
study on the mechanism of its action is warranted.
In literature, multiple COX-independent mechanisms affecting enzyme activity,
TFs, cellular signaling and mitochondrial functions have been proposed4,30,74,86. The studies
described in this dissertation are partly an extension of our earlier observations on the role
of p53 and G6PD in aspirin’s anti-cancer effect. p53, which is often mutated and
inactivated in cancer, has been a subject of study in many laboratories to reactivate and
restore its functions. In this context, several small molecules that have the ability to bind
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to mutant p53 and activate its tumor-suppressor functions have been reported171, but till
date, none of them have been made available for clinical use. Our demonstration of the
ability of aspirin to acetylate wild-type p53 in HCT 116 cells and mutant p53 in HT-29
cancer cells has confirmed the previously reported findings in MDA-MB-231 cancer cells
by our group35. Acetylated p53 was localized to the nuclear compartment in both cell types
suggesting its role as a TF. More importantly, the acetylation of p53 in the cells was
associated with an increase in the expression of its target gene p21CIP1. This suggests the
ability of aspirin to acetylate p53 in other cancer cells and indicates that activation of
mutant p53 is possible through a chemical acetylation reaction. We also identified aspirin
acetylated lysine sites on p53 using MS which included 5 lysines in the DNA binding
domain, 4 in the nuclear localization domain and 1 lysine in the C-terminal
domain(identified with antibody). Among these, 5 sites appear to be common between
aspirin targeted sites and sites that are naturally acetylated by acetyltransferases. Based on
the previously published reports149, while acetylation at K382 by aspirin may account for
the increased stabilization of p53, the acetylation of K120 and K320 by aspirin may have
a direct relevance to the induction of p21CIP1 and Bax gene expression.
Our studies also show that greater acetylation of G6PD was observed in HCT 116
than HT-29 cells by aspirin; accordingly, the inhibition of the G6PD enzyme activity was
higher in HCT 116 cells. In this project, we made an attempt to identify the aspirin targeted
lysine sites on G6PD isoform a that was acetylated in vitro. The most interesting
observation we discovered from the MS data is the ability of aspirin to target the lysine
(K235) in the active site of the enzyme. K235 in isoform a corresponds to K205 in isoform
b. It is very likely that the acetylation of this essential lysine by aspirin contributes to the
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dysfunctioning of the enzyme.
One of the novel findings of this study is the identification of c-Myc as a target of
aspirin and salicylic acid in multiple cancer cell lines. We demonstrated that c-Myc protein
and mRNA are down-regulated suggesting that the regulation occurs at both transcriptional
and post-translational level. In view of the observation that c-Myc is overexpressed in
nearly 20% of all cancers, the demonstration of aspirin’s ability to decrease c-Myc is a
significant finding. We demonstrated that following aspirin exposure, it is rapidly
hydrolyzed to salicylic acid and this occurs within the first 2 h. Since salicylic acid
mimicked all the actions of aspirin, it is likely that aspirin’s effect on c-Myc occurs through
formation of salicylic acid. These observations clearly suggest pathways other than COX,
contributing to aspirin’s chemopreventive actions. Although many investigators have been
attempting to identify a molecule that can inhibit c-Myc function as a strategy to treat
cancer, till date, no effective molecule has been identified. This is because c-Myc is a TF
and it does not have an enzyme activity associated with its function. Therefore, the ability
of salicylic acid to down-regulate c-Myc, as shown in this study, represents an important
finding.
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Figure 6.1 Schematic representation of aspirin targets identified in this dissertation,
as potentially contributing to its anti-cancer effects
Our results suggest that aspirin acetylates p53, increases its DNA binding activity. Aspirin
also acetylates G6PD, and inhibits its enzyme activity, potentially leading to decreased
ribonucleotide synthesis. It remains to be determined whether acetylated p53 inhibits
G6PD activity through direct interaction. Aspirin and its metabolite salicylic acid downregulate c-Myc protein and mRNA levels.
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6.2

Limitations and future directions
• The studies described in dissertation have identified aspirin acetylated sites on

recombinant wild-type p53. However, additional work is required to extend these studies
and to fully characterize aspirin’s ability to acetylate cellular p53, and to identify the
acetylation sites in different mutant p53 forms, and the consequence of this posttranslational modification on the induction of target gene expression. Although, we have
identified 10 lysine residues as the targets of aspirin acetylation on recombinant wild-type
p53, the acetylation targets of aspirin in mutant forms may occur at the same or different
sites, owing to changes in its conformation.
• Future studies are also required to determine a functional role for acetylated p53 in
cells harboring different p53 mutant forms. Hundreds of mutations have been identified in
p53, some mutations lead to partial inactivation, others cause full inactivation. Using DNA
binding assays, p53 reporter, and Chromatin immunoprecipitation assays, it will be
important to determine how acetylated mutant p53 affects p53 functional activity and gene
expression.
• The studies described in this dissertation has identified aspirin acetylated sites on
recombinant G6PD isoform a. Additional studies are required to identify the aspirin
acetylated site in isoform b, in view of the report that isoform b represents the functionally
active form of G6PD. While direct acetylation of G6PD by aspirin at lysine may render the
enzyme dysfunctional, other mechanisms may also contribute to the inactivation of the
enzyme activity. For example, it is possible that acetylated p53 may directly interact with
G6PD to prevent dimerization of G6PD, which is required for the enzyme activity, this
needs to be studied (see Figure 6.1). In addition, extended studies are also required to
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understand how inhibition of G6PD activity by aspirin affects the ribonucleotide synthesis
within cells.
• The downregulation of c-Myc by aspirin and salicylic acid is an important
observation made during the course of this investigation. We speculate that, the decrease
in the c-Myc mRNA levels observed is due to the downregulation of an upstream TF that
regulates the c-Myc gene transcription. This TF involved in c-Myc transcription, affected
by salicylic acid, needs to be identified.
• Animal studies are required to validate the findings we made in cell culture models
on acetylation of p53, G6PD, and downregulation of c-Myc in response to aspirin
treatment.
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